0000000001316435

AUTHOR

Melchiorre Cervello

showing 127 related works from this author

Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines

2018

Neutrophil gelatinase-associated lipocalin (NGAL a.k.a lipocalin 2, lnc2) is a secreted protein which can form a complex with matrix metalloproteinase-9 (MMP9). This MMP9/NGAL complex has been associated with metastasis. MMP9 and NGAL are detected in the urine of patients afflicted with many different types of cancer, including prostate cancer. The effects of p53, NF-κB and the androgen receptor (AR) on the expression of NGAL was examined in four prostate cancer cell lines. Prostate cancer cell lines that are AR negative and expressed either mutant or no p53 (DU145 and PC3) displayed higher levels of NGAL expression compared to the prostate cancer cell lines (LNCaP and 22Rv-1) which are AR …

Male0301 basic medicinep53Cancer ResearchLipocalinMMP9Metastasis03 medical and health sciencesProstate cancerDU145GeneticCell Line Tumorandrogen receptorLNCaPGeneticsmedicineHumansNF-kappaBNGALMolecular BiologyChemistryNF-kappa BProstatic Neoplasmsmedicine.diseaseprostate cancerGene Expression Regulation NeoplasticAndrogen receptor030104 developmental biologyMatrix Metalloproteinase 9Receptors AndrogenCell cultureCancer researchMolecular MedicineTumor Suppressor Protein p53
researchProduct

Histamine and spontaneously released mast cell granules affect the cell growth of human hepatocellular carcinoma cells

2007

The role of mast cells in tumor growth is still controversial. In this study we analyzed the effects of both histamine and pre-formed mediators spontaneously released by mast cells on the growth of two human hepatocellular carcinoma cell lines, HA22T/VGH and HuH-6, with different characteristics of differentiation, biological behavior and genetic defects. We showed that total mast cell releasate, exocytosed granules (granule remnants) and histamine reduced cell viability and proliferation in HuH-6 cells. In contrast, in HA22T/VGH cells granule remnants and histamine induced a weak but significant increase in cell growth. We showed that both cell lines expressed histamine receptors H(1) and …

medicine.medical_specialtyCarcinoma HepatocellularCell SurvivalSurvivinClinical BiochemistryHistamine AntagonistsApoptosisHistamine H1 receptorBiologyRanitidineBiochemistryExocytosisInhibitor of Apoptosis ProteinsHistamine receptorchemistry.chemical_compoundInternal medicineCell Line TumormedicineAnimalsHumansHistamine H4 receptorMast CellsEnterochromaffin-like cellRats WistarMolecular BiologyCells Culturedbeta CateninCell ProliferationCell growthCaspase 3Liver NeoplasmsMast cellMolecular biologyNeoplasm ProteinsRatsEnzyme ActivationEndocrinologymedicine.anatomical_structurechemistryCell cultureCyclooxygenase 2Molecular MedicineReceptors HistamineFemaleTerfenadinePoly(ADP-ribose) PolymerasesMicrotubule-Associated ProteinsHistamineHistamine
researchProduct

Advances in Targeting Signal Transduction Pathways

2012

// James A. McCubrey 1 , Linda S. Steelman 1 , William H. Chappell 1 , Lin Sun 1,2 , Nicole M. Davis 1 , Stephen L. Abrams 1 , Richard A. Franklin 1 , Lucio Cocco 3 , Camilla Evangelisti 4 , Francesca Chiarini 4 , Alberto M. Martelli 3,4 , Massimo Libra 5 , Saverio Candido 5 , Giovanni Ligresti 5 , Grazia Malaponte 5 , Maria C. Mazzarino 5 , Paolo Fagone 5 , Marco Donia 5 , Ferdinando Nicoletti 5 , Jerry Polesel 6 , Renato Talamini 6 , Jorg Basecke 7 , Sanja Mijatovic 8 , Danijela Maksimovic-Ivanic 8 , Michele Milella 9 , Agostino Tafuri 10 , Joanna Dulinska-Litewka 11 , Piotr Laidler 11 , Antonio B. D’Assoro 12 , Lyudmyla Drobot 13 , Kazuo Umezawa 14 , Giuseppe Montalto 15 , Melchiorre Cer…

cancer stem cellsAMPKtherapy resistanceReviewsLibrary scienceAntineoplastic AgentsrafBiologyPI3Kampk03 medical and health sciences0302 clinical medicineCANCER STEM CELLSNeoplasmsAnimalsHumansUniversity medicalMolecular Targeted TherapyAkt; AMPK; Cancer stem cells; Metformin; MTOR; PI3K; Raf; Targeted therapy; Therapy resistanceTreatment resistanceProtein Kinase Inhibitors030304 developmental biology0303 health sciencesRoswell Park Cancer InstituteAktCancer stem cellAKTMTORAMP-ACTIVATED PROTEIN KINASE (AMPK)Raftargeted therapyMetformin3. Good healthGene Expression Regulation NeoplasticCell stressOncologyDrug Resistance NeoplasmDrug Designtargeted therapy; metformin; therapy resistance; pi3k; akt; ampk; cancer stem cells; raf; mtor030220 oncology & carcinogenesisMutationmTORMolecular targetsCancer researchmetforminSignal Transduction
researchProduct

Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases.

2017

Natural products or nutraceuticals promote anti-aging, anti-cancer and other health-enhancing effects. A key target of the effects of natural products may be the regulation of the PI3K/PTEN/Akt/mTORC1/GSK-3 pathway. This review will focus on the effects of curcumin (CUR), berberine (BBR) and resveratrol (RES), on the PI3K/PTEN/Akt/mTORC1/GSK-3 pathway, with a special focus on GSK-3. These natural products may regulate the pathway by multiple mechanisms including: reactive oxygen species (ROS), cytokine receptors, mirco-RNAs (miRs) and many others. CUR is present the root of turmeric (Curcuma longa). CUR is used in the treatment of many disorders, especially in those involving inflammatory p…

0301 basic medicineCancer ResearchCurcuminBerberinemTORC1PharmacologyResveratrolMechanistic Target of Rapamycin Complex 1Protective AgentsNatural product03 medical and health scienceschemistry.chemical_compoundGlycogen Synthase Kinase 3Phosphatidylinositol 3-KinasesBerberineGeneticNeoplasmsOsteoarthritisStilbenesGeneticsPTENHumansCurcumaMolecular BiologyProtein kinase BPI3K/AKT/mTOR pathwayInflammationNatural productsbiologyBerberine; Curcumin; Natural products; ResveratrolPTEN PhosphohydrolaseNeurodegenerative Diseasesbiology.organism_classification030104 developmental biologyBiochemistrychemistryGene Expression RegulationCardiovascular DiseasesResveratrolbiology.proteinCurcuminMolecular MedicineProto-Oncogene Proteins c-aktSignal Transduction
researchProduct

Molecular mechanisms of sorafenib action in liver cancer cells.

2012

Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib evolves, there is increasing interest in defining the mechanisms underlying its anti-tumor activity. Considering that this specific inhibitor could target unexpected molecules depending on the biologic context, a precise understanding of its mechanism of action could be critical to maximize its treatment efficacy, while minimizing adverse effects. Two human HCC cell lines (HepG2 and Huh7), carrying different biological and genetic characteristics, were used in this study to examine the intracellular events leading …

SorafenibDNA ReplicationNiacinamideCarcinoma HepatocellularDNA RepairTranscription GeneticAngiogenesisCell SurvivalPyridinesApoptosisPharmacologyBiologysorafenib HCC mini-chromosome maintenance genes Dickkopf1 Harakiri Acheron/LARP6 YAP1 cell cycle microarray global gene expression analysisCell Line TumormedicineCell AdhesionHumansneoplasmsMolecular BiologyProtein Kinase InhibitorsCell ProliferationYAP1Neovascularization PathologicCell growthGene Expression ProfilingPhenylurea CompoundsBenzenesulfonatesCell CycleLiver NeoplasmsBiological TransportCell BiologyCell cycleSorafenibmedicine.diseasedigestive system diseasesMechanism of actionHepatocellular carcinomaProtein Biosynthesismedicine.symptomMitogen-Activated Protein KinasesLiver cancerDevelopmental Biologymedicine.drugSignal Transduction
researchProduct

Non invasive tools for the diagnosis of liver cirrhosis

2014

Liver cirrhosis (LC), the end stage of many forms of chronic hepatitis of different etiologies is a diffuse process characterized by fibrosis and the conversion of normal liver architecture into structurally abnormal nodules surrounded by annular fibrosis. This chronic progressive clinical condition, leads to liver cell failure and portal hypertension, which can favour the onset of hepatocellular carcinoma. Defining the phase of the natural history is crucial for therapeutic choice and prognosis. Liver biopsy is currently considered the best available standard of reference but it has some limits, so alternative tools have been developed to substitute liver biopsy when assessing liver fibros…

Diagnostic ImagingLiver Cirrhosismedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaBiopsyContrast MediaReviewSeverity of Illness IndexGastroenterologySerum markersPredictive Value of TestsFibrosisInternal medicineUltrasoundBiopsymedicineHumansLiver fibrosis; Liver biopsy; Ultrasound; Elastography; Serum markersmedicine.diagnostic_testbusiness.industryLiver cellGastroenterologyReproducibility of ResultsLiver fibrosiUltrasonography DopplerGeneral MedicineLiver biopsyPrognosismedicine.diseaseLiverLiver biopsyHepatocellular carcinomaElasticity Imaging TechniquesPortal hypertensionRadiologyElastographyElastographybusinessBiomarkers
researchProduct

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.

2012

The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Certain components of these pathways, RAS, NF1, BRAF, MEK1, DUSP5, PP2A, PIK3CA, PIK3R1, PIK3R4, PIK3R5, IRS4, AKT, NFKB1, MTOR, PTEN, TSC1, and TSC2 may also be activated/inactivated by mutations or epigenetic silencing. Upstream mutations in one signaling pathway or even in downstream components of the same pathway can alter the sensitivity of the cells to certain small molecule inhibitors. These pathways have profound effects on proliferative, apoptotic and differentiation pathways. Dysregulation of components of these cas…

MAPK/ERK pathwayPremature agingMAP Kinase Signaling SystemTargeted Therapy Therapy Resistance Mutations Raf Akt PI3K mTORMtorReviewsPi3kPI3KReceptor tyrosine kinaseAkt; Mtor; Mutations; Pi3k; Raf; Targeted therapy; Therapy resistance;Targeted therapyPhosphatidylinositol 3-Kinases03 medical and health sciences0302 clinical medicineAnimalsHumansPTENExtracellular Signal-Regulated MAP KinasesProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biology0303 health sciencesbiologyChemistryTOR Serine-Threonine KinasesAktTherapy resistancePTEN PhosphohydrolaseTargeted TherapyTherapy ResistanceRafProtein phosphatase 2MAP Kinase Kinase Kinases3. Good healthCell biologyOncology030220 oncology & carcinogenesisMutationras ProteinsmTORCancer researchbiology.proteinraf KinasesMitogen-Activated Protein KinasesSignal transductionProto-Oncogene Proteins c-aktMutationsSignal TransductionOncotarget
researchProduct

Emerging Raf inhibitors

2009

The Raf/MAPK kinase/extracellular-signal-regulated kinase pathway is often activated by genetic alterations in upstream signaling molecules. An integral component of this pathway, BRAF, is also activated by mutation, especially in melanoma and thyroid cancers. The Raf/MAPK kinase/extracellular-signal-regulated kinase pathway has profound effects on proliferative, apoptotic and differentiation pathways as well as the sensitivity and resistance to chemotherapeutic drugs.This review discusses targeting of Raf which could control abnormal proliferation in cancer and other proliferative diseases. The important roles that genetics plays in the response of patients to Raf inhibitors is also evalua…

MAPK/ERK pathwayProto-Oncogene Proteins B-rafCell signalingMAP Kinase Signaling SystemSignal transductionrafmedicine.disease_causemekerkmedicineHumanscancerPharmacology (medical)raf inhibitorsExtracellular Signal-Regulated MAP KinasesMelanomaProtein Kinase InhibitorsPharmacologyapoptosis cancer ERK proliferative disorderssignal transductionMitogen-Activated Protein Kinase KinasesApoptosis; Cancer; ERK; Kinases; MEK; Proliferative disorders; Protein phosphorylation; Raf; Raf inhibitors; Signal transductionMutationproliferative disordersapoptosis; cancer; erk; kinases; mek; proliferative disorders; protein phosphorylation; raf; raf inhibitors; signal transduction read more: http://informahealthcare.com/doi/abs/10.1517/14728210903232633business.industryKinaseMelanomaapoptosisCancermedicine.diseaseXenograft Model Antitumor Assaysprotein phosphorylationCell Transformation Neoplastickinasessignal transduction read more: http://informahealthcare.com/doi/abs/10.1517/14728210903232633ApoptosisDrug Resistance NeoplasmCancer researchSignal transductionMitogen-Activated Protein Kinasesbusiness
researchProduct

Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-P…

2017

Over the past fifty years, society has become aware of the importance of a healthy diet in terms of human fitness and longevity. More recently, the concept of the beneficial effects of certain components of our diet and other compounds, that are consumed often by different cultures in various parts of the world, has become apparent. These “healthy” components of our diet are often referred to as nutraceuticals and they can prevent/suppress: aging, bacterial, fungal and viral infections, diabetes, inflammation, metabolic disorders and cardiovascular diseases and have other health-enhancing effects. Moreover, they are now often being investigated because of their anti-cancer properties/po…

0301 basic medicineCancer ResearchCurcuminBerberinemedia_common.quotation_subjectInflammationAntineoplastic AgentsPharmacologyResveratrol03 medical and health scienceschemistry.chemical_compoundNutraceuticalBerberineGeneticNeoplasmsGeneticsMedicineAnimalsHumansMolecular Biologymedia_commonbusiness.industryLongevityMetforminMetformin030104 developmental biologychemistryCardiovascular DiseasesResveratrolCancer cellDietary SupplementsCurcuminMolecular Medicinemedicine.symptombusinessBerberine; Curcumin; Metformin; Resveratrolmedicine.drugSignal TransductionAdvances in biological regulation
researchProduct

Effects of ectopic expression of NGAL on doxorubicin sensitivity.

2012

Neutrophil gelatinase-associated lipocalin (NGAL, a.k.a Lnc2) is a member of the lipocalin family which has diverse roles including stabilizing matrix metalloproteinase-9 from auto-degradation and as siderocalins which are important in the transport of iron. NGAL also has important biological functions involved in immunity and inflammation as well as responses to kidney damage. NGAL expression has also been associated with certain neoplasia and is important in the metastasis of breast cancer. Many advanced cancer patients have elevated levels of NGAL in their urine and it has been proposed that NGAL may be a prognostic indicator for certain cancers (e.g. breast, brain, and others). NGAL exp…

siderocalinColorectal cancerBlotting WesternResistanceBreast NeoplasmsLipocainBiologyLipocalinsiderocalinsMetastasisBreast cancerLcn2Lipocalin-2Proto-Oncogene ProteinsmedicineTumor Cells CulturedHumansDoxorubicinNGALIron transportCell Proliferationdrug resistanceAntibiotics AntineoplasticCancermedicine.diseaseResearch PapersLipocalinsOncologyDocetaxelDrug Resistance NeoplasmDoxorubicinImmunologyCancer researchDoxorubicin; Drug resistance; Iron transport; Lcn2; Lipocalins; MMP-9; NGAL; SiderocalinsEctopic expressionFemalelipocalinMMP-9Colorectal Neoplasmsmedicine.drugAcute-Phase Proteins
researchProduct

Spontaneous cytotoxic activity of eosinophilic granule cells separated from the normal peritoneal cavity ofDicentrarchus labrax

2000

Abstract In this study the spontaneous in vitro cytotoxic activity to tumour cell lines, (K562), by unstimulated sea bass ( Dicentrarchus labrax ) leukocytes was examined by trypan blue exclusion test and lactate dehydrogenase release assay. A high anti-tumour cell line activity of resident peritoneal leukocytes was found at an effector to target ratio (E:T) of 25:1 after incubation for 2 h at 18° C. Rabbit and sheep erythrocytes were not lysed. A low activity was displayed by head kidney and spleen cell populations whereas blood leukocytes revealed no significant activity. The effect of E:T ratio on cytotoxicity as well as microscopy observations suggested that the cytotoxic reaction requi…

Cytotoxicity ImmunologicPathologymedicine.medical_specialtySettore BIO/05 - ZoologiaCell SeparationAquatic SciencePeritoneal cavitychemistry.chemical_compoundLactate dehydrogenaseCentrifugation Density GradientTumor Cells CulturedmedicineAnimalsHumansEnvironmental ChemistryCytotoxic T cellCytotoxicityPeritoneal CavitybiologyOsmolar ConcentrationGranule (cell biology)Dicentrarchus labrax Teleostei cytotoxicity peritoneal cavity eosinophilic granule cellGeneral MedicineCytotoxicity Tests Immunologicbiology.organism_classificationMolecular biologyEosinophilsmedicine.anatomical_structurechemistryCell cultureBassDicentrarchusRabbitsPercollFish & Shellfish Immunology
researchProduct

Expression of IAPs and alternative splice variants in hepatocellular carcinoma tissues and cells.

2005

IAPs (inhibitors of apoptosis proteins) might have a major role in the apoptotic resistance that marks many cancers. The studies on IAPs in human HCC have focused on survivin or XIAP, indicating that their new or increased expression in this tumor is associated with a more unfavorable prognosis. The present results corroborate these findings, emphasizing the role that the coordinated expression of different IAPs and alternative splice variants might play in the adverse biology of hepatocellular carcinoma.

Carcinoma HepatocellularApoptosisX-Linked Inhibitor of Apoptosis ProteinBiologyBioinformaticsGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of ScienceCell Line TumorSurvivinCarcinomamedicineHumansspliceRNA MessengerCell ProliferationCell growthReverse Transcriptase Polymerase Chain ReactionGeneral NeuroscienceAlternative splicingLiver NeoplasmsIntracellular Signaling Peptides and ProteinsProteinsmedicine.diseasePrognosisXIAPbody regionsAlternative SplicingApoptosisDrug Resistance NeoplasmHepatocellular carcinomaCancer researchAnnals of the New York Academy of Sciences
researchProduct

Epidemiology, Risk Factors, and Natural History of Hepatocellular Carcinoma

2002

The incidence of hepatocellular carcinoma is increasing in many countries. The estimated number of new cases annually is over 500,000, and the yearly incidence comprises between 2.5 and 7% of patients with liver cirrhosis. The incidence varies between different geographic areas, being higher in developing areas; males are predominantly affected, with a 2:3 male/female ratio. The heterogeneous geographic distribution reflects the epidemiologic impact of the main etiologic factors and environmental risk, which are the hepatitis B (HBV) and hepatitis C (HCV) viruses. The percentage of cases of hepatocellular carcinoma attributable to HBV worldwide is 52.3% and is higher in Asia where the serop…

Viral Hepatitis VaccinesHepatitis B virusmedicine.medical_specialtyAflatoxin B1Carcinoma HepatocellularCirrhosisPopulationHepacivirusmedicine.disease_causeGastroenterologyGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of ScienceRisk FactorsInternal medicinemedicineCarcinomaHumanseducationHepatitis B viruseducation.field_of_studybusiness.industryGeneral NeuroscienceIncidence (epidemiology)Liver NeoplasmsHepatitis CHepatitis BHepatitis Bmedicine.diseaseHepatitis Cdigestive system diseasesAlcoholsHepatocellular carcinomabusinessAnnals of the New York Academy of Sciences
researchProduct

Cyclooxygenases in hepatocellular carcinoma

2006

Many epidemiological studies demonstrate that treatment with non-steroidal anti-inflammatory drugs (NSAIDs) reduce the incidence and mortality of certain malignancies, especially gastrointestinal cancer. The cyclooxygenase (COX) enzymes are well-known targets of NSAIDs. However, conventional NSAIDs non-selectively inhibit both the constitutive form COX-1, and the inducible form COX-2. Recent evidence indicates that COX-2 is an important molecular target for anticancer therapies. Its expression is undetectable in most normal tissues, and is highly induced by pro-inflammatory cytokines, mitogens, tumor promoters and growth factors. It is now well-established that COX-2 is chronically overexpr…

Carcinoma HepatocellularAngiogenesisBiologymedicine.disease_causeModels BiologicalGene Expression Regulation EnzymologicIn vivomedicineHumansNeoplasm InvasivenessGastrointestinal cancerEnzyme InhibitorsCell growthAnti-Inflammatory Agents Non-SteroidalLiver NeoplasmsGastroenterologyGeneral MedicineHCCSmedicine.diseasedigestive system diseasesGene Expression Regulation NeoplasticEditorialModels ChemicalCyclooxygenase 2Hepatocellular carcinomaImmunologyCyclooxygenase 1Cancer researchCarcinogenesisLiver cancer
researchProduct

Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells

2005

WISPs (Wnt-induced secreted proteins) are members of the CCN (CTGF/Cyr61/Nov) family involved in fibrotic disorders and tumorigenesis. They have a typical structure composed of four conserved cysteine-rich modular domains, but variants of CCN members lacking one or more modules, generated by alternative splicing or gene mutations, have been described in various pathological conditions. WISP genes were first described as downstream targets of the Wnt signaling pathway, which is frequently altered in human hepatocellular carcinoma (HCC). In the present study, WISP mRNA expression was analyzed by RT-PCR in four human HCC cell lines (HepG2, HuH-6, HuH-7, HA22T/VGH). Our results show for the fir…

Carcinoma HepatocellularWISPHepatocellular carcinomaApoptosisGene mutationBiologymedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyCCN Intercellular Signaling ProteinsWntalternative splicingHistory and Philosophy of ScienceCell Line TumorProto-Oncogene ProteinsCCN Intercellular Signaling ProteinsmedicineHumansRNA MessengerGeneDNA PrimersOncogene ProteinsGeneticsCCNModels GeneticReverse Transcriptase Polymerase Chain ReactionGeneral NeuroscienceLiver NeoplasmsAlternative splicingIntracellular Signaling Peptides and ProteinsWnt signaling pathwaydigestive system diseasesNeoplasm ProteinsInsulin-Like Growth Factor Binding ProteinsRepressor ProteinsCTGFCYR61Cancer researchIntercellular Signaling Peptides and ProteinsRNACarcinogenesisWISPWntTranscription Factors
researchProduct

Expression of the IAPs in multidrug resistant tumor cells

2003

We have investigated the expression of the IAPs (inhibitory of apoptosis proteins) in the human HL-60 leukemia and in its multidrug resistant, P-glycoprotein (P-gp) over-expressing variant, HL-60R. HL-60R exhibits resistance to apoptosis induced from P-gp substrate drugs and also from other triggers (cisplatin, TNF-alpha, Fas ligation, TRAIL, IFN-gamma and serum starvation) not related to the multidrug transporter. Except for c-IAP-1 mRNA, HL-60R significantly over-expressed both the mRNAs and the proteins of all the IAPs studied, i.e. c-IAP-1, c-IAP-2, XIAP, NAIP and survivin. Determination of the DNA-binding capacity of NF-kappaB (p50 or p65 subunits) indicated that, while HL-60 cells sho…

Cancer ResearchBlotting WesternCellApoptosisHL-60 CellsBiologyInhibitor of Apoptosis Proteinsmultidrug resistanceSurvivinmedicineHumansRNA MessengerCisplatinOncogeneReverse Transcriptase Polymerase Chain ReactionNF-kappa BProteinsGeneral MedicineIAPCell cycleapoptosiMolecular biologyDrug Resistance MultipleXIAPGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyDrug Resistance NeoplasmApoptosisCancer researchNAIPmedicine.drugOncology Reports
researchProduct

Aromatase and amphiregulin are correspondingly expressed in human liver cancer cells

2009

Human hepatocellular carcinoma (HCC) is associated with high mortality rates, being the third most common cause of cancer death worldwide. Although estrogens have been implicated in HCC, their potential role in development and/or progression of this malignancy remains unclear. In this study we investigated mRNA and protein expression of aromatase (Aro) and amphiregulin (AREG) in relation to estrogen receptors (ERs), in HepG2, Huh7, and HA22T human malignant liver cell lines, using RT-PCR and Western blot analyses. Aro expression was significantly higher (approximately 13-fold, P= 0.003) in HepG2 cells than in Huh7 cells, while no Aro expression could be detected in HA22T cells. Interestingl…

medicine.medical_specialtyEGF Family of ProteinsBlotting WesternEstrogen receptorAmphiregulinGeneral Biochemistry Genetics and Molecular BiologyAromataseHistory and Philosophy of ScienceAmphiregulinWestern blotInternal medicineCell Line TumormedicineHumansEstrogen receptors hepatocellular carcinoma amphiregulinAromataseDNA PrimersGlycoproteinsbiologymedicine.diagnostic_testBase SequenceReverse Transcriptase Polymerase Chain ReactionGeneral NeuroscienceLiver cellLiver NeoplasmsEstrogen Receptor alphamedicine.diseasedigestive system diseasesBlotEndocrinologyCell cultureHepatocellular carcinomabiology.proteinCancer researchIntercellular Signaling Peptides and Proteins
researchProduct

GSK-3 in liver diseases: Friend or foe?

2020

Liver diseases, including hepatitis due to hepatitis B or C virus infection, non-alcoholic fatty liver disease, and hepatocellular carcinoma pose major challenges for overall health due to limited curative treatment options. Thus, there is an urgent need to develop new therapeutic strategies for the treatment of these diseases. A better understanding of the signaling pathways involved in the pathogenesis of liver diseases can help to improve the efficacy of emerging therapies, mainly based on pharmacological approaches, which influence one or more specific molecules involved in key signal transduction pathways. These emerging therapies are very promising for the prevention and treatment of …

0301 basic medicineSignaling pathwaysDruggabilityDiseaseBioinformaticsNon-alcoholic fatty liver disease (NAFLD)Glycogen Synthase Kinase 303 medical and health sciences0302 clinical medicineGSK-3Glycogen synthase kinase 3 (GSK-3)AnimalsHumansMedicineHepatitis B virus (HBV)Molecular Targeted TherapyEnzyme InhibitorsHepatocellular carcinoma (HCC)Molecular BiologyHepatitisbusiness.industryLiver DiseasesFatty liverDisease ManagementHepatitis C virus (HCV)Cell BiologyHepatitis Bmedicine.disease030104 developmental biologyGene Expression RegulationMultigene Family030220 oncology & carcinogenesisHepatocellular carcinomaHost-Pathogen InteractionsDisease SusceptibilitySignal transductionbusinessBiomarkersSignal TransductionBiochimica et Biophysica Acta (BBA) - Molecular Cell Research
researchProduct

Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis

2020

Non-alcoholic fatty liver disease (NAFLD) is becoming the main cause of liver disease in Western countries, especially in morbidly obese patients (MOPs). The proprotein convertase subtilisin/kexin type 9 (PCSK9) has been recently studied because of its possible involvement in the pathogenesis of NAFLD, but its role, at least in MOPs, is still controversial. The aim of this study was to clarify the correlation between the circulating levels of the PCSK9 protein (cPCSK9) and its hepatic expression with the severity of liver damage in a population of MOPs with NAFLD undergoing bariatric surgery. PCSK9 mRNA was positively correlated with FASN, PPARγ and PPARα mRNAs, while no significant differe…

AdultMale0301 basic medicinemedicine.medical_specialtySettore MED/06 - Oncologia MedicaPopulationBariatric SurgeryInflammation030204 cardiovascular system & hematologySeverity of Illness IndexPathogenesisNon-alcoholic fatty liver disease (NAFLD)03 medical and health sciencesBallooning degenerationLiver disease0302 clinical medicineInternal medicinemedicineHumansMorbidly obese patients (MOPs)educationMolecular Biologyeducation.field_of_studybusiness.industryPCSK9Fatty liverCell BiologyMiddle AgedLipid Metabolismmedicine.diseaseObesity MorbidFatty LiverProprotein convertase subtilisin/kexin type 9 (PCSK9)030104 developmental biologyEndocrinologyLiverFemaleProprotein Convertase 9medicine.symptomSteatosisbusiness
researchProduct

Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and…

2002

We studied the human HL60 leukemia cell line and its multidrug resistant (MDR) variant HL60R. In contrast to the HL60, HL60R showed an inability to undergo apoptosis from doxorubicin (Dox) or other different stimuli, including cisplatin, Fas ligation and serum withdrawal. HL60R cells lost surface Fas expression, but we found no evidence that Fas/FasL mediates the apoptotic effects of Dox in HL60. P-glycoprotein (P-gp) did not seem to play a major role as a specific inhibitor of apoptosis. In fact, the P-gp inhibitor verapamil reversed only partially the resistance to Dox-induced apoptosis of the MDR cells. In addition, it did not modify the rate of apoptosis induced from the other stimuli i…

Cancer ResearchProgrammed cell deathTime FactorsChromosomal Proteins Non-HistoneSurvivinDown-RegulationAntineoplastic AgentsApoptosisHL-60 CellsNerve Tissue ProteinsBiologyInhibitor of apoptosisFas ligandInhibitor of Apoptosis ProteinsInhibitory Concentration 50SurvivinTumor Cells CulturedHumansATP Binding Cassette Transporter Subfamily B Member 1RNA Messengerfas ReceptorP-glycoproteinInhibitor of apoptosis domainCaspase 3Reverse Transcriptase Polymerase Chain ReactionProteinsFlow CytometryNeuronal Apoptosis-Inhibitory ProteinNeoplasm ProteinsCell biologyProto-Oncogene Proteins c-bcl-2OncologyDoxorubicinDrug Resistance NeoplasmApoptosisCaspasesbiology.proteinInsect ProteinsNAIPCisplatinMicrotubule-Associated ProteinsCancer Letters
researchProduct

Induction of apoptosis by the adenosine derivative IB-MECA in parental or multidrug-resistant HL-60 leukemia cells: possible relationship to the effe…

2004

<i>Background:</i> The effects of the A<sub>3</sub> adenosine receptor (A<sub>3</sub>AR) agonist IB-MECA were examined in HL-60 leukemia and in its multidrug-resistant variant HL-60R cells. <i>Methods:</i> Cytotoxicity was evaluated by MTS assays and apoptosis by flow cytometry analyses of DNA fragmentation and phosphatidylserine exposure. The mRNAs of A<sub>3</sub>AR and inhibitor of apoptosis proteins (IAPs) were determined by RT-PCR. <i>Results:</i> A<sub>3</sub>AR expression was similar in HL-60 and HL-60R cells. At ≧100 µ<i>M</i>, IB-MECA exhibited strong cytotoxic and apoptotic effects in H…

AgonistProgrammed cell deathAdenosinemedicine.drug_classApoptosisHL-60 CellsBiologyInhibitor of apoptosisInhibitor of Apoptosis ProteinsDrug DiscoverymedicineNeoplasmHumansPharmacology (medical)PharmacologyGeneral Medicinemedicine.diseaseAdenosine A3 receptorFlow CytometryAdenosineDrug Resistance MultipleLeukemiaInfectious DiseasesOncologyBiochemistryApoptosisDrug Resistance NeoplasmA 3 adenosine receptor IB-MECA Apoptosis Multidrug resistance Inhibitor of apoptosis proteinsCancer researchmedicine.drugChemotherapy
researchProduct

New landscapes and horizons in hepatocellular carcinoma therapy

2020

Hepatocellular carcinoma (HCC), is the sixth most frequent form of cancer and leads to the fourth highest number of deaths each year. HCC results from a combination of environmental factors and aging as there are driver mutations at oncogenes which occur during aging. Most of HCCs are diagnosed at advanced stage preventing curative therapies. Treatment in advanced stage is a challenging and pressing problem, and novel and well-tolerated therapies are urgently needed. We will discuss further advances beyond sorafenib that target additional signaling pathways and immune checkpoint proteins. The scenario of possible systemic therapies for patients with advanced HCC has changed dramatically in …

OncologySorafenibmedicine.medical_specialtySettore MED/09 - Medicina InternaCarcinoma Hepatocellularmedicine.medical_treatmentAntineoplastic AgentsReviewTargeted therapy03 medical and health sciences0302 clinical medicineInternal medicinemedicineBiomarkers TumorcancerHumansHCC030304 developmental biology0303 health sciencesbusiness.industryagingLiver NeoplasmsCancerCell BiologyImmunotherapyGenetic Therapymedicine.diseaseOmicstargeted therapyImmune checkpointdigestive system diseases3. Good healthGene Expression Regulation Neoplastic030220 oncology & carcinogenesisHepatocellular carcinomaimmunotherapybusinessmedicine.drugPersonal genomicsAging (Albany NY)
researchProduct

Management of liver failure: from transplantation to cell-based therapy

2011

The severe shortage of deceased donor organs has driven a search for alternative methods of treating liver failure. In this context, cell-based regenerative medicine is emerging as a promising interdisciplinary field of tissue repair and restoration, able to contribute to improving health in a minimally invasive fashion. Several cell types have allowed long-term survival in experimental models of liver injury, but their therapeutic potential in humans should be regarded with deep caution, because few clinical trials are currently available and the number of patients enrolled so far is too small to assess benefits versus risks. This review summarizes the current literature on the physiologi…

education.field_of_studymedicine.medical_specialtytherapy.liver transplantationbusiness.industryPopulationMesenchymal stem cellLiver failureClinical uses of mesenchymal stem cellsReviewBioinformaticsRegenerative medicineLiver regenerationSurgeryTransplantationstem cellGeneral Earth and Planetary SciencesMedicineStem celleducationbusinessInduced pluripotent stem cellGeneral Environmental Science
researchProduct

Frequent Alteration of the Yin Yang 1/Raf-1 Kinase Inhibitory Protein Ratio in Hepatocellular Carcinoma

2011

The transcription factor Yin Yang 1 (YY1) can favor several aspects of tumorigenesis. In turn, Raf-1 Kinase Inhibitor Protein (RKIP) inhibits the oncogenic activities of MAPK and NF-κB pathways and promotes drug-induced apoptosis. Mutual influences between YY1 and RKIP may exist, and there are already separate evidences that relevant increases in YY1 and reductions in RKIP occur in hepatocellular carcinoma (HCC). However, the levels of the two factors have never been concomitantly examined in HCC. We evaluated by RT-PCR the mRNA levels of YY1, YY1AP, RKIP, and survivin in 35 clinical HCCs (91% HCV-related), in their adjacent cirrhotic tissues and in 6 healthy livers. Immunohistochemical ana…

AdultLiver CirrhosisMaleMAPK/ERK pathwayCarcinoma HepatocellularSettore MED/09 - Medicina InternaSurvivinCell Cycle ProteinsPhosphatidylethanolamine Binding ProteinSettore MED/08 - Anatomia PatologicaBiologymedicine.disease_causeBiochemistryInhibitor of Apoptosis ProteinsSurvivinGeneticsmedicineHumansRNA MessengerHepatocellular carcinomaYY1RKIPMolecular BiologyTranscription factorYY1 Transcription FactorAgedAged 80 and overSettore MED/12 - GastroenterologiaHepatocellular carcinoma Yin Yang 1 Raf-1 Kinase Inhibitor Protein Yin Yang 1-associated proteinKinaseYY1Liver NeoplasmsNuclear ProteinsMiddle AgedHCCSmedicine.diseaseGene Expression Regulation NeoplasticLiverHepatocellular carcinomaembryonic structuresSettore BIO/14 - FarmacologiaCancer researchMolecular MedicineFemaleSettore SECS-S/01 - StatisticaCarcinogenesisTranscription FactorsBiotechnologyOMICS: A Journal of Integrative Biology
researchProduct

Potential Uses of Olive Oil Secoiridoids for the Prevention and Treatment of Cancer: A Narrative Review of Preclinical Studies

2021

The Mediterranean diet (MD) is a combination of foods mainly rich in antioxidants and anti-inflammatory nutrients that have been shown to have many health-enhancing effects. Extra-virgin olive oil (EVOO) is an important component of the MD. The importance of EVOO can be attributed to phenolic compounds, represented by phenolic alcohols, hydroxytyrosol, and tyrosol, and to secoiridoids, which include oleocanthal, oleacein, oleuropein, and ligstroside (along with the aglycone and glycosidic derivatives of the latter two). Each secoiridoid has been studied and characterized, and their effects on human health have been documented by several studies. Secoiridoids have antioxidant, anti-inflammat…

0301 basic medicineSettore MED/09 - Medicina InternaSettore CHIM/10 - Chimica Degli AlimentiMediterranean dietAnti-Inflammatory AgentsReviewDiet MediterraneanAntioxidantsCyclopentane Monoterpeneslcsh:Chemistrychemistry.chemical_compound0302 clinical medicineGlucosidesNeoplasmsIridoidslcsh:QH301-705.5SpectroscopyTraditional medicineGeneral MedicinePhenylethyl AlcoholComputer Science Applications030220 oncology & carcinogenesissecoiridoidsIridoid GlucosidesAntineoplastic AgentsoleocanthalCatalysisInorganic Chemistry03 medical and health sciencesPhenolsOleuropeinOleocanthalmedicineAnimalsHumanscanceroleaceinPhysical and Theoretical ChemistryOlive OilMolecular BiologyPyransAldehydesOrganic ChemistryCancermedicine.diseaseTyrosol030104 developmental biologyAglyconelcsh:Biology (General)lcsh:QD1-999chemistryoleuropeinligstrosideHydroxytyrosolOlive oilInternational Journal of Molecular Sciences
researchProduct

Prostaglandin E2 receptors and COX enxymes in human hepatocellular carcinoma: role in the regulation of cell growth

2008

The aim of this study was to investigate the expression of prostaglandin E 2 receptors (EP 1-4 ), cyclooxygenase-1 (COX-1), and COX-2 in nontumor and tumor human liver tissues, and also to evaluate the antitumor activity of selective EP 1 receptor antagonist used alone or in combination with COX-1 and COX-2 selective inhibitors. Semiquantitative PCR analyses revealed that EP 1-4 , COX-1, and COX-2 mRNA expression was detected in nearly all the tissue samples assayed, although with a high variability between nontumor and tumor tissues. In vitro EP 1 receptor antagonist inhibited anchorage-independent cell growth and reduced the viability of hepatocellular carcinoma (HCC) cells in a dose-depe…

Malemedicine.medical_specialtyEP receptorSettore MED/09 - Medicina InternaCarcinoma Hepatocellularmedicine.drug_classProstaglandinmedicine.medical_treatmentGeneral Biochemistry Genetics and Molecular Biologyhepatocellular carcinoma (HCC)History and Philosophy of ScienceInternal medicineCell Line Tumormedicinecell growthHumansReceptors Prostaglandin EProstaglandin E2ReceptorAgedCOX-1ChemistryCell growthGeneral NeuroscienceLiver NeoplasmsCOX-2Middle Agedmedicine.diseaseReceptor antagonistNSAIDIn vitroCyclooxygenaseEndocrinologyProstaglandin-Endoperoxide SynthasesHepatocellular carcinomaSettore BIO/14 - FarmacologiaCancer researchFemaleLiver cancerCell DivisionProstaglandin Emedicine.drug
researchProduct

Sex hormones and risk of liver tumor.

2007

The liver is morphologically and functionally modulated by sex hormones. Long-term use of oral contraceptives (OCs) and anabolic androgenic steroids (AASs) can induce both benign (hemangioma, adenoma, and focal nodular hyperplasia [FNH]) and malignant (hepatocellular carcinoma [HCC]) hepatocellular tumors. Hepatic adenomas (HAs) are rare, benign neoplasms usually occurring in young women, the development and the complications of which have been related to the strength of OCs and the duration of their use. HA incidence has fallen since the introduction of pills containing smaller amounts of estrogens. FNH is a benign lesion, most commonly seen in young women, which is thought to represent a …

MaleRiskmedicine.medical_specialtyCirrhosisLiver tumorAdenomamedicine.drug_classPhysiologyBiologyGeneral Biochemistry Genetics and Molecular BiologyAndrogenAromataseHistory and Philosophy of ScienceInternal medicinemedicineHumansSex RatioHCCGonadal Steroid HormonesHepatitisGeneral NeuroscienceLiver NeoplasmsFocal nodular hyperplasiaCancermedicine.diseaseEstrogenEndocrinologyLiverReceptors EstrogenEstrogenReceptors AndrogenHepatocellular carcinomaFemaleBenign liver tumorAnnals of the New York Academy of Sciences
researchProduct

Down-regulation of wild-type β-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 and leukemia HL60 cells: a possible role in the gro…

2000

Hl60 cellsbiologymedicine.medical_treatmentWild typeGrowth inhibitorymedicine.diseaseBiochemistryLeukemiaCytokineDownregulation and upregulationCateninmedicinebiology.proteinCancer researchInterleukin 6Biochemical Society Transactions
researchProduct

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

2011

Chemotherapy remains a commonly used therapeutic approach for many cancers. Indeed chemotherapy is relatively effective for treatment of certain cancers and it may be the only therapy (besides radiotherapy) that is appropriate for certain cancers. However, a common problem with chemotherapy is the development of drug resistance. Many studies on the mechanisms of drug resistance concentrated on the expression of membrane transporters and how they could be aberrantly regulated in drug resistant cells. Attempts were made to isolate specific inhibitors which could be used to treat drug resistant patients. Unfortunately most of these drug transporter inhibitors have not proven effective for ther…

MAPK/ERK pathwayPTENTumor suppressor genekinase inhibitorPhysiologymedicine.medical_treatmentClinical Biochemistrygrowth factor receptorAntineoplastic AgentsDrug resistancePharmacologyBiologyTargeted therapy03 medical and health sciencesMicePhosphatidylinositol 3-Kinases0302 clinical medicineGrowth factor receptormedicinePTENAnimalsHumansExtracellular Signal-Regulated MAP KinasesProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biology0303 health sciencesTOR Serine-Threonine KinasesPTEN PhosphohydrolaseCell BiologyMAP Kinase Kinase Kinases3. Good healthErbB ReceptorsDrug Resistance Neoplasm030220 oncology & carcinogenesisMutationCancer researchbiology.proteinraf KinasesProto-Oncogene Proteins c-aktDrug resistance therapeutic sensitivity targeted therapy RAF ERKACUTE MYELOID LEUKAEMIASignal TransductionJournal of cellular physiology
researchProduct

Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.

2012

Hepatocellular carcinoma (HCC) is the most common liver cancer, accounting for 90% of primary liver cancers. In the last decade it has become one of the most frequently occurring tumors worldwide and is also considered to be the most lethal of the cancer systems, accounting for approximately one third of all malignancies. Although the clinical diagnosis and management of early-stage HCC has improved significantly, HCC prognosis is still extremely poor. Furthermore, advanced HCC is a highly aggressive tumor with a poor or no response to common therapies. Therefore, new effective and well-tolerated therapy strategies are urgently needed. Targeted therapies have entered the field of anti-neopl…

SorafenibOncologymedicine.medical_specialtyPathologyCarcinoma Hepatocellularmedicine.medical_treatmentReviewsAntineoplastic AgentsDiseasesignal transduction inhibitorsModels BiologicalTargeted therapyInternal medicinemedicineCarcinomacancerAnimalsHumansMolecular Targeted TherapyHCCneoplasmsCause of deathbusiness.industryTherapies InvestigationalLiver NeoplasmsCancerDrugs Investigationalmedicine.diseasetargeted therapyVEGFdigestive system diseasesOncologyHepatocellular carcinomaRas/Raf/MEK/ERKHCC targeted therapy VEGF Ras/Raf/MEK/ERK PI3K/Akt/PTEN/mTOR signal transduction inhibitors cancPI3K/Akt/PTEN/mTORLiver cancerbusinessmedicine.drugSignal Transduction
researchProduct

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer

2020

Glycogen synthase kinase 3 (GSK-3) is a serine/threonine (S/T) protein kinase. Although GSK-3 originally was identified to have functions in regulation of glycogen synthase, it was subsequently determined to have roles in multiple normal biochemical processes as well as various disease conditions. GSK-3 is sometimes referred to as a moonlighting protein due to the multiple substrates and processes which it controls. Frequently, when GSK-3 phosphorylates proteins, they are targeted for degradation. GSK-3 is often considered a component of the PI3K/PTEN/AKT/GSK-3/mTORC1 pathway as GSK-3 is frequently phosphorylated by AKT which regulates its inactivation. AKT is often active in human cancer a…

natural productnatural productsmTORC1Reviewmacromolecular substancesProtein Serine-Threonine KinasesGlycogen Synthase Kinase 3GSK-3NeoplasmsHumansPhosphorylationProtein kinase AGlycogen synthaselcsh:QH301-705.5Protein kinase BWnt Signaling PathwayPI3K/AKT/mTOR pathwayGSK-3drug resistancenaturalproductsbiologyChemistryWnt signaling pathwayGeneral Medicinetargeted therapyCell biologylcsh:Biology (General)biology.proteinSignal transductionProto-Oncogene Proteins c-akt
researchProduct

Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy.

2016

Various, diverse molecules contribute to the tumor microenvironment and influence invasion and metastasis. In this review, the roles of neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) in the tumor microenvironment and sensitivity to therapy will be discussed. The lipocalin family of proteins has many important functions. For example when NGAL forms a complex with MMP-9 it increases its stability which is important in cancer metastasis. Small hydrophobic molecules are bound by NGAL which can alter their entry into and efflux from cells. Iron transport and storage are also influenced by NGAL activity. Regulation of iron levels is important for survival…

0301 basic medicinemedicine.medical_treatmentDrug resistance; Iron transport; Lcn2; Lipocalins; MMP-9; NGAL; SiderocalinsAcute-Phase ProteinLipocalinLipocalinMetastasisTargeted therapyAntineoplastic Agent0302 clinical medicineNeoplasmsTumor MicroenvironmentNeoplasm MetastasisNGALProto-Oncogene ProteinMedicine (all)SiderocalinsLipocalinsNeoplasm MetastasiMatrix Metalloproteinase 9030220 oncology & carcinogenesismedicine.symptomSignal transductionMMP-9HumanProtein BindingSignal TransductionSiderocalinAntineoplastic AgentsInflammationBiologyModels Biological03 medical and health sciencesLcn2Lipocalin-2Proto-Oncogene ProteinsmedicineHumansIron transportMolecular BiologyTumor microenvironmentInnate immune systemCell Biologymedicine.disease030104 developmental biologyDrug resistanceCancer cellImmunologyCancer researchNeoplasmAcute-Phase Proteins
researchProduct

Circulating intercellular adhesion molecule-1 in chronic hepatitis C patients with normal or elevated aminotransferase before and after alpha-interfe…

2001

<i>Objectives:</i> Intercellular adhesion molecule-1 (ICAM-1) plays a fundamental role during liver inflammation. In fact, weak ICAM-1 expression is physiologically restricted to the endothelium of portal vessels and to sinusoidal lining cells, but it becomes markedly evident on sinusoidal lining cells and at the surface of hepatocytes during inflammatory liver diseases. The aim of this study was to evaluate the behaviour of soluble ICAM-1 (sICAM-1) in chronic hepatitis C (CH-C) patients with persistently normal aminotransferase in comparison with patients with CH-C and elevated aminotransferase, and its changes during α-interferon (IFN) therapy. Immunohistochemical localization…

AdultMaleIntercellular Adhesion Molecule-1Alpha interferonInflammationInterferon alpha-2BiologyChronic hepatitis CAntiviral Agentsα-InterferonLiver diseaseChronic hepatitisVirologymedicineHumansAspartate Aminotransferasesα interferonInterferon-alphaAlanine TransaminaseAdhesionIntercellular adhesion molecule-1Hepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsInfectious DiseasesImmunologyCancer researchFemalemedicine.symptomLiver diseaseIntracellular
researchProduct

Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells.

2017

// James A. McCubrey 1 , Timothy L. Fitzgerald 2 , Li V. Yang 3 , Kvin Lertpiriyapong 4 , Linda S. Steelman 1 , Stephen L. Abrams 1 , Giuseppe Montalto 5,6 , Melchiorre Cervello 6 , Luca M. Neri 7 , Lucio Cocco 8 , Alberto M. Martelli 8 , Piotr Laidler 9 , Joanna Dulinska-Litewka 9 , Dariusz Rakus 10 , Agnieszka Gizak 10 , Ferdinando Nicoletti 11 , Luca Falzone 11 , Saverio Candido 11 and Massimo Libra 11 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA 2 Department of Surgery, Brody School of Medicine at East Carolina University, Greenville, NC, USA 3 Department of Internal Medicine, Hematology/Oncology Section, Brody Sc…

0301 basic medicineOncologyGerontologycancer stem cellsmedicine.medical_specialtyEpithelial-Mesenchymal TransitionReviewPI3KNO03 medical and health sciencesGlycogen Synthase Kinase 30302 clinical medicineCancer stem cellGSK-3Internal medicinemicroRNAmedicineAnimalsHumansPTENEpithelial–mesenchymal transitionProtein kinase BPI3K/AKT/mTOR pathwayGSK-3biologybusiness.industryAnimalCancer stem cellAktWnt signaling pathwayWnt/beta-cateninMicroRNAMicroRNAsGSK-3 cancer stem cells Wnt/beta-catenin PI3K Akt030104 developmental biologyOncology030220 oncology & carcinogenesisNeoplastic Stem Cellsbiology.proteinNeoplastic Stem CellAkt; GSK-3; PI3K; Wnt/beta-catenin; cancer stem cellsbusinessHumanSignal Transduction
researchProduct

Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells

2015

Sorafenib (Sor), an effective chemiotherapeutic drug utilized against hepatocellular carcinoma (HOC), robustly interacts with nonionic amphiphilic cyclodextrin (aCD, SC6OH), forming, in aqueous solution, supramolecular complexes that behave as building blocks of highly water-dispersible colloidal nanoassemblies. SC6OH/Sor complex has been characterized by complementary spectroscopic techniques, such as UV-vis, steady-state fluorescence and anisotropy, resonance light scattering and H-1 NMR. The spectroscopic evidences and experiments carried out in the presence of an adamantane derivative, which competes with drug for CD cavity, agree with the entrapment of Sor in aCD, pointing out the role…

NiacinamideErythrocytesPolymers and PlasticsCell SurvivalAdamantaneDrug CompoundingSupramolecular chemistryBioengineeringNanotechnologyAdamantaneAntineoplastic AgentsBinding CompetitiveHemolysisAmphiphilic Cyclodextrins; Nanoparticles; Sorafenib; HCC cellsHCC cellsBiomaterialschemistry.chemical_compoundSurface-Active AgentsIn vivoCell Line TumorAmphiphileMaterials ChemistryHumanschemistry.chemical_classificationCyclodextrinsAqueous solutionCyclodextrinPhenylurea CompoundsSorafenibFluorescenceCombinatorial chemistrydigestive system diseasesNanostructuresBINDING INTERACTION THERAPY PHARMACOKINETICS BIOAVAILABILITY NANOPARTICLESDrug LiberationKineticsnanoassembliecyclodextrinchemistryDelayed-Action PreparationsProton NMRHepatocytes
researchProduct

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health

2011

William H. Chappell 1 , Linda S. Steelman 1,2 , Jacquelyn M. Long 2 , Ruth C. Kempf 2 , Stephen L. Abrams 1 , Richard A. Franklin 1 , Jorg Basecke 3 , Franca Stivala 4 , Marco Donia 4 , Paolo Fagone 4 , Graziella Malaponte 4 , Maria C. Mazzarino 4 , Ferdinando Nicoletti 4 , Massimo Libra 4 , Danijela Maksimovic-Ivanic 5 , Sanja Mijatovic 5 , Giuseppe Montalto 6 , Melchiorre Cervello 7 , Piotr Laidler 8 , Michele Milella 9 , Agostino Tafuri 10 , Antonio Bonati 11 , Camilla Evangelisti 12 , Lucio Cocco 12 , Alberto M. Martelli 12,13 , and James A. McCubrey 1 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University 2 Department of Physics, Greenville, N…

MAPK/ERK pathwayAgingmedicine.medical_treatmentDrug ResistancerafPI3KTargeted therapycombination therapyPhosphatidylinositol 3-Kinases0302 clinical medicineTARGETED THERAPYCANCER STEM CELLSNeoplasmsCancer Stem CellsMedicineExtracellular Signal-Regulated MAP Kinases0303 health sciencesCombination TherapybiologyTOR Serine-Threonine KinasesMTORHuman health Ras inhibitors MEK ERKTargeted TherapyDiscovery and development of mTOR inhibitors3. Good healthDRUG RESISTANCECell Transformation NeoplasticOncology030220 oncology & carcinogenesismTORraf KinasesPremature agingMAP Kinase Signaling SystemReviewsSenescence03 medical and health sciencesCell Line TumorHumansPTENProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biologyMitogen-Activated Protein Kinase Kinasesbusiness.industryAKTAktagingPTEN PhosphohydrolaseRafTransplantationSENESCENCEImmunologyras Proteinsbiology.proteinCancer researchaging; akt; cancer stem cells; combination therapy; drug resistance; mtor; pi3k; raf; senescence; targeted therapybusinessProto-Oncogene Proteins c-akt
researchProduct

Antitumor effects of the novel NF-κB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and …

2006

We tested the novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in the hepatic cancer (HCC) HepG2, HA22T/VGH and HuH-6 cells. The sensitivity to the cell growth inhibitory and apoptotic effects of the agent increased along with the levels of constitutively activated NF-kappaB, which were low in HepG2 and higher in HA22T/VGH and HuH-6. In HA22T/VGH, DHMEQ exhibited synergy with cisplatin. In the same cells, DHMEQ exerted dose-dependent decreases in the nuclear levels of activated NF-kappaB and attenuated NF-kappaB activation by cisplatin. It down-regulated Bcl-XL mRNA in a dose-dependent manner and up-regulated that of Bcl-XS. It also decreased interleukin 6 (IL-6), NAIP and, …

CisplatinCancer Researchmedicine.medical_specialtyOncogeneCell growthmedicine.medical_treatmentBiologyXIAPEndocrinologyCytokineOncologyApoptosisInternal medicineCancer cellmedicineCancer researchAutocrine signallingmedicine.drugInternational Journal of Oncology
researchProduct

Biocompatible Lipid Nanoparticles as Carriers to Improve Curcumin Efficacy in Ovarian Cancer Treatment

2017

Curcumin is a natural molecule with proved anticancer efficacy on several human cancer cell lines. However, its clinical application has been limited due to its poor bioavailability. Nanocarrier-based drug delivery approaches could make curcumin dispersible in aqueous media, thus overtaking the limits of its low solubility. The aim of this study was to increase the bioavailability and the antitumoral activity of curcumin, by entrapping it into nanostructured lipid carriers (NLCs). For this purpose here we describe the preparation and characterization of three kinds of curcumin-loaded NLCs. The nanosystems allowed the achievement of a controlled release of curcumin, the amounts of curcumin r…

nanostructured lipid carriers curcumin drug release cancer epithelial ovarian cellsCurcuminNanoparticleAdministration Oral02 engineering and technologyPharmacologynanostructured lipid carrier03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsNanoparticleSettore BIO/10 - BiochimicamedicineHumanscancerParticle SizeDrug Carrierdrug releaseCell ProliferationOvarian NeoplasmsDrug CarriersOvarian NeoplasmChemistry (all)General ChemistryLipid021001 nanoscience & nanotechnologyBiocompatible materialmedicine.diseaseControlled releaseLipidsBioavailabilitychemistryAgricultural and Biological Sciences (all)Settore CHIM/09 - Farmaceutico Tecnologico Applicativo030220 oncology & carcinogenesisDrug deliveryCurcuminNanoparticlesFemaleNanocarriers0210 nano-technologyGeneral Agricultural and Biological SciencesOvarian cancerDrug Delivery Systemepithelial ovarian cellHuman
researchProduct

Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells

2015

Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib was evaluated. The obtained systems showed characteristics suitable as drug delivery systems for the treatment of hepatocellular carcinoma (HCC) through parenteral administration. The use of a mixture between a solid lipid (tripalmitin) with a liquid lipid (Captex 355 EP/NF or Miglyol 812) to prepare NLC systems could give a higher drug loading capacity and a longer term stability during storage than that obtained by using only solid lipids. The obtained nanoparticles showed a nanometer size and high negative zeta potential values. Scansion electron microscopy (SEM) of the sorafenib loaded NLC…

NiacinamideSorafenibDrugCell Survivalmedia_common.quotation_subjectnanostructured lipid carriersPharmaceutical ScienceAntineoplastic AgentsPharmacologyHemolysischemistry.chemical_compoundNanostructured lipid carriers Sorafenib Drug release Angiogenesis inhibitor HepatocarcinomamedicineZeta potentialHumansParticle SizeChromatography High Pressure LiquidTriglyceridesdrug releasemedia_commonDrug CarriersPhenylurea CompoundsHep G2 Cellsmedicine.diseaseLipidsControlled releasedigestive system diseasesIn vitroDrug Liberationangiogenesis inhibitorchemistryhepatocarcinomaSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDelayed-Action PreparationsHepatocellular carcinomaTripalmitinDrug deliveryMicroscopy Electron ScanningNanoparticlessorafenibCaprylatesmedicine.drug
researchProduct

Nanostructured Lipid Carriers-Containing Anticancer Compounds: Preparation, Characterization, and Cytotoxicity Studies

2007

This article describes the development of nanostructured lipid carriers (NLC) as colloidal carriers for two antitumor compounds that possess a remarkable antineoplastic activity. But their limited stability and low solubility in water could give a very low parenteral bioavailability. Results revealed an enhancement of the cytotoxicity effect of drug-loaded NLC on human prostate cancer (PC-3) and human hepatocellular carcinoma (HuH-6, HuH-7) cell lines with respect to that of both free drugs. Results of characterization studies strongly support the potential application of these drugs-loaded NLC as prolonged delivery systems for lipophilic drugs by several administration routes, in particula…

Materials scienceCell SurvivalDrug CompoundingPharmaceutical ScienceNanoparticleAntineoplastic AgentsPharmacologynanostructured lipid carrierHuman prostatehuman prostate carcinoma cellPlasmaCell Line TumorElectrochemistryHumansParticle SizeSolubilityCytotoxicityChromatography High Pressure LiquidDrug CarriersGeneral Medicineantitumor drugLipidsControlled releaseBioavailabilitySolubilityPlasma chemistryNanoparticleshuman hepatocellular carcinoma cellcontrolled releaseDrug metabolism
researchProduct

The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism

2012

In a previous work of ours dehydroxymethyl-epoxyquinomicin (DHMEQ), an inhibitor of NF-κB, was shown to induce apoptosis through Reactive Oxygen Species (ROS) production in hepatoma cells. The present study demonstrated that DHMEQ cooperates with Celecoxib (CLX) to decrease NF-κB DNA binding and to inhibit cell growth and proliferation more effectively than treatment with these single agents alone in the hepatoma cell lines HA22T/VGH and Huh-6. ROS production induced by the DHMEQ-CLX combination in turn generated the expression of genes involved in endoplasmic reticulum (ER) stress and silencing TRB3 mRNA significantly decreased DHMEQ-CLX-induced cell growth inhibition. Moreover, the DHMEQ-…

Cancer ResearchCarcinoma HepatocellularAntineoplastic AgentsApoptosisCell Cycle ProteinsProtein Serine-Threonine KinasesBiologyDHMEQ Celecoxib NF-jB CD95/CD95L Liver cancer cellsCell Line TumorSurvivinHumansGene silencingfas ReceptorProtein kinase BCell ProliferationSulfonamidesGene knockdownCyclooxygenase 2 InhibitorsCyclohexanonesCell growthEndoplasmic reticulumLiver NeoplasmsNF-kappa BDrug SynergismEndoplasmic Reticulum StressMolecular biologyAcetylcysteineRepressor ProteinsOncologyCelecoxibCell cultureApoptosisBenzamidesCancer researchPyrazolesPoly(ADP-ribose) PolymerasesReactive Oxygen SpeciesCancer Letters
researchProduct

Gamma enolase expression as early marker of neuronal differentiation of murine neuroblastoma cells N-115

2012

In this study we determined the levels of gamma enolase mRNA in mouse neuroblastoma cell line N-115 at early period of induction of differentiation by serum withdrawal. The expression of gamma enolase was examined by Northern blot analysis of total RNA extracted from cells induced for different lengths of time. We found a 3-fold increase in the level of gamma enolase mRNA after 24 hours of induction of differentiation and higher levels were detected in cells induced for longer time, reaching a 10-fold increase after four days.

Messenger RNAPeriod (gene)Clinical BiochemistryNeuronal differentiationBiomedical EngineeringBioengineeringCell BiologyMouse NeuroblastomaBiologyGamma-EnolaseMolecular biologyMurine neuroblastomaCell cultureNorthern blotBiotechnologyCytotechnology
researchProduct

Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways

2012

Background & Aims: miR-224 is up-regulated in human HCCs as compared to both paired peri-tumoral cirrhotic tissues and cirrhotic livers without HCC. Here, we have cloned the miR-224 regulatory region and characterized its transcriptional regulation by the NFκB-dependent inflammatory pathways. Methods: Mature miRNA expression was evaluated by a 2 step stem-loop real-time RT-PCR. The recruitment of polymerase II and transcription factors on the pre-miR-224 promoter has been assessed by ChIPSeq and ChIP. Results: We found miR-224 levels strongly up-regulated in both peri-tumoral cirrhotic livers and HCC samples as compared to normal livers. In silico analysis of the putative miR-224 promoter r…

LipopolysaccharidesLiver CirrhosisMaleCarcinoma HepatocellularTranscription GeneticLiver CirrhosiLipopolysaccharideBiologyCell MovementCell Line TumormicroRNATranscriptional regulationHumansNF kappa BHCCmir-224; nfκb; hcc; mirnas; transcriptionTranscription factorLymphotoxin-alphamiRNAAgedHepatologymiRNAs; HCC; miR-224; Transcription; NF kappa BTumor Necrosis Factor-alphaLiver NeoplasmsNF-kappa BMicroRNAmiR-224HCCSMiddle AgedNFKB1Up-RegulationMicroRNAsIκBαLiverLiver NeoplasmCase-Control StudiesImmunologymiRNAsCancer researchTumor necrosis factor alphaFemaleSignal transductionCase-Control StudieTranscriptionNFκBHumanSignal Transduction
researchProduct

Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals

2018

Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10%. Mutations at the TP53 gene are readily detected in pancreatic tumors isolated from PDAC patients. We have investigated the effects of restoration of wild-type (WT) TP53 activity on the sensitivity of pancreatic cancer cells to: chemotherapy, targeted therapy, as well as, nutraceuticals. Upon introduction of the WT-TP53 gene into the MIA-PaCa-2 pancreatic cancer cell line, the sensitivity to drugs used to treat pancreatic cancer cells such as: gemcitabine, fluorouracil (5FU), cisp…

0301 basic medicineCancer ResearchPaclitaxelendocrine system diseasesmedicine.medical_treatmentTargeted therapeuticIrinotecanDeoxycytidineTargeted therapyGlycogen Synthase Kinase 303 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumorPancreatic cancerGeneticsmedicineHumansDoxorubicinTP53Signal transduction inhibitorneoplasmsMolecular BiologyCell ProliferationCisplatinChemotherapybusiness.industryPancreatic Neoplasmmedicine.diseaseGemcitabinedigestive system diseasesGemcitabinePancreatic NeoplasmsOxaliplatin030104 developmental biologyPaclitaxelchemistryFluorouracil030220 oncology & carcinogenesisCancer researchMolecular MedicineFluorouracilCisplatinbusinessDrug sensitivityHumanSignal Transductionmedicine.drug
researchProduct

Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

2006

AIM: To evaluate the immunohistochemical localization of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) on tumor tissue specimens from patients with hepatocellular carcinoma (HCC) and the serum levels of IL-6 and sIL-6R in a group of patients with HCC as well as liver cirrhosis (LC) in a group of patients with LC alone and in a control group. METHODS: Three groups of subjects were studied: group I (n = 83) suffering from HCC and LC, group II (n = 72) suffering from LC alone and group III (n = 42) as healthy controls. All patients had hepatitis C virus infection. Serum IL-6 and IL-6R levels were determined using a commercially available ELISA kit. Immunohistochemistry was performed using the…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentChronic liver diseaseGastroenterologyInternal medicineCarcinomaMedicineHumansInterleukin 6ReceptorCytokineAgedNeoplasm Stagingbiologybusiness.industryInterleukin-6Chronic liver diseaseLiver NeoplasmsGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryReceptors Interleukin-6digestive system diseasesCytokineHepatocellular carcinomabiology.proteinImmunohistochemistryFemalebusinessRapid CommunicationWorld journal of gastroenterology
researchProduct

Nanotechnology applications for the therapy of liver fibrosis.

2013

Chronic liver diseases represent a major global health problem both for their high prevalence worldwide and, in the more advanced stages, for the limited available curative treatment options. In fact, when lesions of different etiologies chronically affect the liver, triggering the fibrogenesis mechanisms, damage has already occurred and the progression of fibrosis will have a major clinical impact entailing severe complications, expensive treatments and death in end-stage liver disease. Despite significant advances in the understanding of the mechanisms of liver fibrinogenesis, the drugs used in liver fibrosis treatment still have a limited therapeutic effect. Many drugs showing potent ant…

Liver CirrhosisSettore MED/09 - Medicina InternaAntifibrotic drugs CirrhosiLiver fibrosisChemistry PharmaceuticalLiver fibrosisCellPharmacologyBioinformaticsAntifibrotic drugsLiver diseaseNanoparticleHepatic stellate cellsIn vivoFibrosisMedicineNanotechnologyAnimalsHumansTopic HighlightAdverse effectHepatic stellate cellDrug Carriersbusiness.industryTherapeutic effectGastroenterologyLiver fibrosiGeneral Medicinemedicine.diseasemedicine.anatomical_structureNanomedicineTreatment OutcomeCirrhosisHepatic stellate cellNanoparticlesbusinessWorld journal of gastroenterology
researchProduct

Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors …

2019

Abstract Mutations at the TP53 gene are readily detected (approximately 50–75%) in pancreatic ductal adenocarcinoma (PDAC) patients. TP53 was previously thought to be a difficult target as it is often mutated, deleted or inactivated on both chromosomes in certain cancers. In the following study, the effects of restoration of wild-type (WT) TP53 activity on the sensitivities of MIA-PaCa-2 pancreatic cancer cells to the MDM2 inhibitor nutlin-3a in combination with chemotherapy, targeted therapy, as well as, nutraceuticals were examined. Upon introduction of the WT-TP53 gene into MIA-PaCa-2 cells, which contain a TP53 gain of function (GOF) mutation, the sensitivity to the MDM2 inhibitor incre…

0301 basic medicineCancer ResearchNutlin-3aSettore MED/09 - Medicina Internaendocrine system diseasesmedicine.medical_treatmentmedicine.disease_causePiperazinesTargeted therapy0302 clinical medicineTP53MutationbiologyChemistryImidazolesProto-Oncogene Proteins c-mdm2OxaliplatinTargeted TherapeuticsDrug sensitivity; Nutlin-3a; Nutraceuticals; Targeted therapeutics; TP53030220 oncology & carcinogenesisMolecular MedicineMdm2NutraceuticalNutraceuticalsSignal transductionCarcinoma Pancreatic DuctalSignal Transductionmedicine.drugDrug sensitivityAntineoplastic AgentsIrinotecan03 medical and health sciencesCell Line TumorPancreatic cancerGeneticsmedicineHumansMolecular BiologyneoplasmsChemotherapymedicine.diseasedigestive system diseasesOxaliplatinPancreatic Neoplasms030104 developmental biologyCell cultureDietary Supplementsbiology.proteinCancer researchTERAPÊUTICA MÉDICATumor Suppressor Protein p53
researchProduct

GSK-3 as potential target for therapeutic intervention in cancer

2014

// James A. McCubrey 1 , Linda S. Steelman 1 , Fred E. Bertrand 2 , Nicole M. Davis 1 , Melissa Sokolosky 1 , Steve L. Abrams 1 , Giuseppe Montalto 3 , Antonino B. D’Assoro 4 , Massimo Libra 5 , Ferdinando Nicoletti 5 , Roberta Maestro 6 , Jorg Basecke 7,8 , Dariusz Rakus 9 , Agnieszka Gizak 9 Zoya Demidenko 10 , Lucio Cocco 11 , Alberto M. Martelli 11 and Melchiorre Cervello 12 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University Greenville, NC, USA 2 Department of Oncology, Brody School of Medicine at East Carolina University Greenville, NC, USA 3 Biomedical Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy …

cancer stem cellsNotchmedicine.medical_treatmentReviewmacromolecular substancesPI3KTargeted therapyGlycogen Synthase Kinase 3GSK-3Cancer stem cellNeoplasmsmedicinePTENAnimalsHumansRapamycinProtein kinase BPI3K/AKT/mTOR pathwayGSK-3; cancer stem cells; Wnt/beta-catenin; PI3K; Akt; mTOR; Hedgehog; Notch; Targeted Therapy; Therapy Resistance; Mutations RapamycinGSK-3Roswell Park Cancer InstitutebiologyAkt; Cancer stem cells; GSK-3; Hedgehog; MTOR; Mutations; Notch; PI3K; Rapamycin; Targeted therapy; Therapy resistance; Wnt/beta-cateninAnimalAktWnt/beta-cateninCancerTargeted TherapyTherapy Resistancemedicine.disease3. Good healthOncologybiology.proteinCancer researchmTORHedgehogMutationsHuman
researchProduct

The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment

2020

The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified because of its key role in the regulation of glycogen synthesis. However, it is now well-established that GSK-3 performs critical functions in many cellular processes, such as apoptosis, tumor growth, cell invasion, and metastasis. Aberrant GSK-3 activity has been associated with many human diseases, including cancer, highlighting its potential therapeutic relevance as a target for anticancer therapy. Recently, newly emerging data have demonstrated the pivotal role of GSK-3 in the anticancer immune response. In the last few years, many GSK-3 inhibitors have been developed, and some are currently being te…

medicine.medical_treatmentT cellsReviewmacromolecular substancesNK cellsMetastasisGlycogen Synthase Kinase 3MiceImmune systemCancer immunotherapyGSK-3NeoplasmsPD-1medicineAnimalsHumanscancerGlycogen synthaselcsh:QH301-705.5GSK-3biologyKinasebusiness.industryCancerGeneral MedicineImmunotherapymedicine.diseasesmall molecule inhibitorsDisease Models Animalglycogen synthase kinase-3 (GSK-3)lcsh:Biology (General)Cancer researchbiology.proteinCTLA-4immunotherapybusiness
researchProduct

Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells

2017

AbstractHepatocellular carcinoma (HCC) is one of the common malignancies and is an increasingly important cause of cancer death worldwide. Surgery, chemotherapy, and radiation therapy extend the 5-year survival limit in HCC patients by only 6%. Therefore, there is a need to develop new therapeutic approaches for the treatment of this disease. The orally bioavailable proteasome inhibitor MLN2238 (ixazomib) has been demonstrated to have anticancer activity. In the present study, we investigated the preclinical therapeutic efficacy of MLN2238 in HCC cells through in vitro and in vivo models, and examined its molecular mechanisms of action. MLN2238 inhibited cell viability in human HCC cells He…

Boron Compounds0301 basic medicineCancer ResearchCarcinoma HepatocellularMyeloidCell cycle checkpointImmunologyCellGlycineAntineoplastic AgentsArticleIxazomibAntineoplastic AgentMice03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compound0302 clinical medicinemedicineAnimalsHumansViability assaylcsh:QH573-671Boron CompoundAnimallcsh:Cytologybusiness.industryLiver NeoplasmsCell Biologydigestive system diseases3. Good health030104 developmental biologymedicine.anatomical_structurechemistryLiver NeoplasmCell cultureApoptosis030220 oncology & carcinogenesisProteasome inhibitorCancer researchbusinessProteasome InhibitorsHumanmedicine.drugCell Death & Disease
researchProduct

Downregulation of wild-type β-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: a possible role in the growth-regulatory effe…

2001

We investigated the antitumour effects of interleukin 6 (IL-6) on hepatocarcinoma HepG2 cells, endowed with high levels of a mutated, non-degradable, beta-catenin. IL-6 produced minimal growth-inhibitory effects and no apoptosis or gross changes in cell adhesion. Interestingly, however, it caused a consistent decrease in the cytoplasmic levels of wild-type, but not of mutated, beta-catenin protein. There was no effect on E-cadherin or gamma-catenin and a reduction in alpha-catenin occurred only at high concentrations. IL-4, a non-related cytokine, did not modify the content of beta-catenin. IL-6 did not influence beta-catenin mRNA levels. LiCl, a potent inhibitor of Glycogen Synthase Kinase…

Cancer ResearchCarcinoma Hepatocellularmedicine.medical_treatmentBlotting WesternDown-RegulationApoptosisEnzyme-Linked Immunosorbent AssayBiologyDownregulation and upregulationGSK-3Tumor Cells CulturedmedicineHumansRNA MessengerInterleukin 6beta CateninInterleukin 4Interleukin-6Cell growthLiver NeoplasmsWild typeCell biologyCytoskeletal ProteinsCytokineOncologyCateninTrans-ActivatorsCancer researchbiology.proteinEuropean Journal of Cancer
researchProduct

Heat Shock Protein 70 Serum Levels Differ Significantly in Patients with Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma

2014

Members of the heat shock protein 70 (HSP70) family play an important role in assisting protein folding, preventing protein aggregation and transport of proteins across membranes under physiological conditions. Following environmental (i.e., irradiation, chemotherapy), physiological (i.e., cell growth, differentiation), and pathophysiological (i.e., inflammation, tumorigenesis) stress, the synthesis of heat shock proteins (HSPs) is highly up-regulated, whereas protein synthesis in general is reduced. In contrast to normal cells, many tumor entities including hepatocellular carcinoma (HCC) overexpress HSP70, the major-stress-inducible member of the HSP70 family, present it on their cell surf…

medicine.medical_specialtyPathologyCirrhosismedicine.medical_treatmentliver cirrhosisImmunologyInflammationmedicine.disease_causeGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineImmunology and AllergyHCCprognostic biomarker030304 developmental biologyOriginal Research0303 health sciencesChemotherapyserum HSP70business.industryHcc ; Chronic Hepatitis ; Inflammation ; Liver Cirrhosis ; Prognostic Biomarker ; Serum Hsp70medicine.diseasePathophysiology3. Good healthHsp70HCC serum HSP70 prognostic biomarker chronic hepatitis inflammation liver cirrhosisinflammation030220 oncology & carcinogenesisHepatocellular carcinomachronic hepatitismedicine.symptomCarcinogenesisbusinessFrontiers in Immunology
researchProduct

GSK-3? Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutra…

2021

Glycogen synthase kinase-3 (GSK-3) is a regulator of signaling pathways. KRas is frequently mutated in pancreatic cancers. The growth of certain pancreatic cancers is KRas-dependent and can be suppressed by GSK-3 inhibitors, documenting a link between KRas and GSK-3. To further elucidate the roles of GSK-3β in drug-resistance, we transfected KRas-dependent MIA-PaCa-2 pancreatic cells with wild-type (WT) and kinase-dead (KD) forms of GSK-3β. Transfection of MIA-PaCa-2 cells with WT-GSK-3β increased their resistance to various chemotherapeutic drugs and certain small molecule inhibitors. Transfection of cells with KD-GSK-3β often increased therapeutic sensitivity. An exception was observed wi…

Berberineendocrine system diseasesmedicine.medical_treatmentRegulatormedicine.disease_causeDeoxycytidinePiperazinesTargeted therapychemotherapeutic drugsTargeted therapyNitrophenolsBreast cancerGSK-3BGlycolysisMolecular Targeted TherapyNeoplasm Metastasistargeted therapy;lcsh:QH301-705.5Tumor Stem Cell AssaySulfonamidesTumorbiologyChemistryGeneral MedicineTransfectionMetforminDisease ProgressionMCF-7 CellsFemaleKRASNutraceuticalsFluorouracilSignal transductionGlycolysisSignal TransductionBCL2bcl-X ProteinAntineoplastic AgentsBreast Neoplasmsmacromolecular substancesAdenocarcinomaArticleCell LineInhibitory Concentration 50Cell Line TumorThiadiazolesmedicineDiabetes MellitusKRasHumansGlycogen synthaseProtein Kinase InhibitorsCell ProliferationChemotherapeu-tic drugsGlycogen Synthase Kinase 3 betaGSK-3βAdenylate KinaseBiphenyl Compoundsnutraceuticals;PDACβ-cateninGemcitabine?-cateninMalariaPancreatic Neoplasmslcsh:Biology (General)MCF-7DoxorubicinDietary SupplementsCancer researchbiology.protein
researchProduct

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mtor pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

2011

Dysregulated signaling through the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways is often the result of genetic alterations in critical components in these pathways or upstream activators. Unrestricted cellular proliferation and decreased sensitivity to apoptotic-inducing agents are typically associated with activation of these pro-survival pathways. This review discusses the functions these pathways have in normal and neoplastic tissue growth and how they contribute to resistance to apoptotic stimuli. Crosstalk and commonly identified mutations that occur within these pathways that contribute to abnormal activation and cancer growth will also be addressed. Finally the recently described …

MaleMAPK/ERK pathwayAgingMAP Kinase Signaling SystemCancer aging RAF MEK mTORApoptosisReviewBiologyPI3KModels BiologicalApoptosis; Cancer; Kinases; MEK; MTOR; PI3K; Protein phosphorylation; RAF; Signal transductionMicePhosphatidylinositol 3-Kinases03 medical and health sciences0302 clinical medicineCancer stem cellNeoplasmscancerAnimalsHumansPTENProtein kinase BCellular SenescencePI3K/AKT/mTOR pathwayCell Proliferation030304 developmental biology0303 health sciencesKinaseTOR Serine-Threonine KinasesapoptosisPTEN PhosphohydrolaseRafCell BiologyMEKprotein phosphorylation3. Good healthCell biologyCrosstalk (biology)kinases030220 oncology & carcinogenesisMutationmTORCancer researchbiology.proteinFemaleraf KinasesProto-Oncogene Proteins c-aktCell agingsignal transduction
researchProduct

Corrigendum to "poly (ADP-ribose) polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells" [Biochim. B…

2018

Fig. 1. The effects of the DHMEQ–Olaparib combination on HCC cells. (A) Cells were treated for 72 hwith the indicated concentrations of DHMEQ–Olaparib and cell viability was assessed by MTS assays. The DHMEQ–Olaparib combination showed synergistic inhibition of cell viability in Hep3B cells and additive inhibition in Huh7 cells. Combination index (CI) values are indicated above the bar. Data are expressed as percent cell growth and are the mean ± SD of three separate experiments (each of which was performed in triplicate). *p b 0.05 and **p b 0.01 versus each agent alone. (B) Cells were treated for 24 h with DHMEQ (μg/ml) or Olaparib (μM) alone or in combination, allowed to grow for 14 days…

Cell growthPoly ADP ribose polymeraseCellCaspase 3Cell BiologyTransfectionBiologyMolecular biologyOlaparibchemistry.chemical_compoundmedicine.anatomical_structurechemistryApoptosismedicineViability assayMolecular BiologyBiochimica et biophysica acta. Molecular cell research
researchProduct

NAIP-deltaEx10-11: a novel splice variant of the apoptosis inhibitor NAIP differently expressed in drug-sensitive and multidrug-resistant HL60 leukem…

2002

Alterations of neuronal apoptosis inhibitory protein (NAIP), a member of the inhibitory of apoptosis protein (IAP) family of inhibitors of apoptosis, have been previously associated with different neurodegenerative disorders. This study indicated the existence of a novel NAIP splice variant. This isoform, NAIP-deltaEx10-11, was found in tumor cell lines of different origin and in normal adult brain. Analysis of the putative protein predicted that the NAIP variant lacks part of the third BIR domain as well as the COOH-terminal tail of regular NAIP. This might suggest that it is endowed with a reduced antiapoptotic activity. This view is supported by the fact that NAIP-deltaEx10-11 mRNA and p…

Gene isoformCancer ResearchApoptosis InhibitorHL60ApoptosisHL-60 CellsNerve Tissue ProteinsBiologyExonchemistry.chemical_compoundmedicineRNA PrecursorsTumor Cells CulturedHumansProtein IsoformsRNA NeoplasmSequence DeletionGeneticsBrain ChemistryAlternative splicingHematologyExonsmedicine.diseaseDrug Resistance MultipleNeuronal Apoptosis-Inhibitory ProteinNeoplasm ProteinsProtein Structure TertiaryLeukemiaAlternative SplicingOncologychemistryApoptosisDrug Resistance NeoplasmCancer researchNAIPLeukemia research
researchProduct

Response to antiviral therapy and hepatic expression of cyclooxygenases in chronic hepatitis C

2007

OBJECTIVES: The aims of this study were to investigate the expression of cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2) in chronic hepatitis C (CHC) by immunohistochemistry, based on the hypothesis that COXs expression could vary according to genotype, viral load, liver steatosis, BMI and response to therapy and to determine whether the addition of selective COX inhibitors could have a rationale in increasing the efficacy of antiviral therapy. METHODS: We used 35 formalin-fixed, paraffin-embedded liver tissue samples obtained by needle biopsy from patients with CHC (17F/18M) with one of two types of genotype (1b and 3a). The presence of COX-1 and COX-2 in the cytoplasm of hepatocyt…

MaleSteatosisGene ExpressionHepacivirusChronic hepatitis CGastroenterologychemistry.chemical_compoundmedicine.diagnostic_testFatty liverGastroenterologyMiddle AgedImmunohistochemistryRecombinant ProteinsCyclooxygenaseTreatment OutcomeLiverRNA ViralFemaleViral loadmedicine.drugAdultmedicine.medical_specialtyAdolescentGenotypeCombination therapyAlpha interferonInterferon alpha-2Antiviral AgentsInternal medicineRibavirinBiopsymedicineHumansInterferon alfaAgedStaining and LabelingHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C AntibodiesHepatitis C Chronicmedicine.diseasechemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesImmunologyCyclooxygenase 1SteatosisbusinessInterferon-αEuropean Journal of Gastroenterology & Hepatology
researchProduct

Significance of Autologous Interleukin-6 Production in the HA22T/VGH Cell Model of Hepatocellular Carcinoma

2006

Cancer cells may often support their own growth, survival, and drug resistance by autocrine/paracrine loops based on the production of different factors; results from us and others have shown that similar interleukin-6 (IL-6)-related loops are operative in multiple myeloma and prostate or renal cancer. Because this aspect has not been investigated in detail for hepatocellular carcinoma (HCC), we have examined it in HA22T/VGH cells. These differ from other primary liver cancer cell lines (that is, HepG2, HuH-6, and HuH-7) in that enzyme-linked immunosorbent assay (ELISA) showed the HA22T/VGH cells to secrete remarkable amounts of IL-6 (16.8 ng/10(6) cells/24 h); this production, due to const…

Settore MED/09 - Medicina InternaCarcinoma HepatocellularCurcuminCellBiologyautocrine cellgrowth stimulatory loopModels BiologicalGeneral Biochemistry Genetics and Molecular BiologyAntibodiesFlow cytometryParacrine signallingHistory and Philosophy of SciencemedicineCytokine Receptor gp130Tumor Cells CulturedHumansNF-kBRNA Small InterferingReceptorAutocrine signallingNF-k Bmedicine.diagnostic_testCyclohexanonesGeneral Neuroscienceinterleukin-6Cell MembraneLiver NeoplasmsNF-kappa Bhepatocellular carcinomaMolecular biologyReceptors Interleukin-6medicine.anatomical_structureCell cultureCancer cellBenzamidesbiology.proteinSettore BIO/14 - Farmacologiaautocrine cell growth stimulatory loopAntibody
researchProduct

The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells

2006

Two isoforms of cyclooxygenase (COX) are known, and to date most studies have implicated COX-2 in the development and progression of various human cancers. Increasing evidence suggests that COX-1 may also play a similar role. Indeed, we have recently observed that the dual COX-1/COX-2 inhibitor indomethacin induces apoptosis in human hepatocellular carcinoma (HCC) cell lines more effectively than the selective COX-2 inhibitors, possibly implicating COX-1 in HCC. In this study we investigated the expression of COX-1 in non-tumor and malignant human liver tissues, as well as the effects of the highly selective COX-1 inhibitor SC-560 on cell growth and apoptosis in human HCC cell lines. Expres…

Malemedicine.medical_specialtyCarcinoma HepatocellularCellApoptosisBiologyGene Expression Regulation EnzymologicCell Line TumorInternal medicineSurvivinGeneticsmedicineHumansCyclooxygenase InhibitorCyclooxygenase InhibitorsRNA MessengerAgedCell ProliferationOncogeneCell growthApoptosiGeneral MedicineMiddle AgedCell cycleImmunohistochemistryXIAPGene Expression Regulation NeoplasticEndocrinologymedicine.anatomical_structureCyclooxygenase 2ApoptosisCell culturePyrazoleCyclooxygenase 1Cancer researchPyrazolesFemaleHumanInternational Journal of Molecular Medicine
researchProduct

Targeting breast cancer initiating cells: advances in breast cancer research and therapy

2014

Over the past 10 years there have been significant advances in our understanding of breast cancer and the important roles that breast cancer initiating cells (CICs) play in the development and resistance of breast cancer. Breast CICs endowed with self-renewing and tumor-initiating capacities are believed to be responsible for the relapses which often occur after various breast cancer therapies. In this review, we will summarize some of the key developments in breast CICs which will include discussion of some of the key genes implicated: estrogen receptor (. ER), HER2, BRCA1, TP53, PIK3CA, RB, P16INK1 and various miRs as well some drugs which are showing promise in targeting CICs. In additio…

OncologyCancer Researchmedicine.medical_specialtyKey genesmedicine.medical_treatmentEstrogen receptorAntineoplastic AgentsBreast NeoplasmsMiRCancer stem cells; ER; HER2; Hormonal therapy; MiRs; Targeted therapy; Therapy resistanceTargeted therapyMiRsTargeted therapyBreast cancerCancer stem cellInternal medicineHER2GeneticsmedicineHumansTreatment resistanceskin and connective tissue diseasesMolecular Biologybusiness.industryCancer stem cellsTherapy resistanceProteinsmedicine.diseaseClinical researchERNeoplastic Stem CellsMolecular MedicineHormonal therapyFemalebusinessHormonal therapyCancer stem cells HER2 ER miRs Targeted therapy Hormonal therapy Therapy resistance
researchProduct

Preface: Advances in Molecular Targets for Therapeutics in Resistant Cancers

2014

business.industryGeneticsMolecular targetsMolecular MedicineMedicineComputational biologybusinessBiochemistryBiotechnologyForum on Immunopathological Diseases and Therapeutics
researchProduct

Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies

2009

The prospect of improved cancer therapy using Solid Lipid Nanoparticles (SLNs) as drug delivery system is promising. Sev- eral obstacles frequently encountered with anticancer compounds, such as poor drug solubility, are overcome by delivering them using SLN. Moreover, the intravenous administration of drugs into SLNs can potentially enhance drug blood circulation time and improve drug per- formance by inducing accumulation into tumours by enhanced permeability and retention (EPR) effect. This paper deals with the devel- opment of SLN containing nimesulide, a non-steroidal anti-inflammatory drug with antitumour effect and low solubility in water. Here, SLNs carrying nimesulide were prepared…

DrugMaterials sciencemedia_common.quotation_subjectsolid lipid nanoparticles nimesulide drug deliveryBiomedical EngineeringPharmaceutical ScienceMedicine (miscellaneous)BioengineeringPharmacologyIn vitroSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoSolid lipid nanoparticleDrug deliveryZeta potentialmedicineSolubilityCytotoxicityBiotechnologymedia_commonNimesulidemedicine.drugCurrent Nanoscience
researchProduct

Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy

2012

An area of therapeutic interest in cancer biology and treatment is targeting the cancer stem cell, more appropriately referred to as the cancer initiating cell (CIC). CICs comprise a subset of hierarchically organized, rare cancer cells with the ability to initiate cancer in xenografts in genetically modified murine models. CICs are thought to be responsible for tumor onset, self-renewal/maintenance, mutation accumulation and metastasis. CICs may lay dormant after various cancer therapies which eliminate the more rapidly proliferating bulk cancer (BC) mass. However, CICs may remerge after therapy is discontinued as they may represent cells which were either intrinsically resistant to the or…

PTENgerminal mutationchemotherapeuticmedicine.medical_treatmentAntineoplastic AgentsPI3KTargeted therapyMetastasisMice03 medical and health sciencesTARGETED THERAPY0302 clinical medicineCancer stem cellNeoplasmsradiologicalDrug DiscoverymedicineAnimalsHumansPTENAkt; mTOR; PI3K; PTEN; Targeted therapy; Therapeutic sensitivityPI3K/AKT/mTOR pathway030304 developmental biologyPharmacologyBiological Products0303 health sciencesbiologyAKTMTORAktCD44Wnt signaling pathwayCancertargeted therapymedicine.disease3. Good healththerapeutic sensitivityxenografts030220 oncology & carcinogenesisImmunologymTORNeoplastic Stem CellsCancer researchbiology.proteinCurrent Pharmaceutical Design
researchProduct

The association of variants in PNPLA3 and GRP78 and the risk of developing hepatocellular carcinoma in an Italian population

2016

// Daniele Balasus 1, * , Michael Way 2, * , Caterina Fusilli 3 , Tommaso Mazza 3 , Marsha Y. Morgan 2 , Melchiorre Cervello 4 , Lydia Giannitrapani 1 , Maurizio Soresi 1 , Rosalia Agliastro 5 , Manlio Vinciguerra 2, 6 , Giuseppe Montalto 1, 4 1 Biomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy 2 Institute for Liver & Digestive Health, Division of Medicine, Royal Free Campus, University College London, London, UK 3 IRCCS Casa Sollievo della Sofferenza, Bioinformatics Unit, San Giovanni Rotondo (FG), Italy 4 Institute of Biomedicine and Molecular Immunology, National Research Council (C.N.R.), Palermo, Italy 5 Immunohematology and Trans…

Malehepatitis C virusSettore MED/09 - Medicina InternaGenome-wide association studyCohort StudiesLiver diseasesingle nucleotide polymorphisms0302 clinical medicineGene FrequencyRisk FactorsEpidemiologyhepatitis C viruEndoplasmic Reticulum Chaperone BiPSicilyHeat-Shock ProteinsLiver NeoplasmsTransfusion medicineHepatitis Chepatocellular carcinomaMiddle Aged3. Good healthOncologyrisk factor030220 oncology & carcinogenesisHepatocellular carcinomaCohort030211 gastroenterology & hepatologyFemaleResearch Papergenetic variantmedicine.medical_specialtyCarcinoma HepatocellularGenotypeSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciencesInternal medicinemedicineHumansGenetic Predisposition to DiseaseAllelesAgedbusiness.industrygenetic variantsMembrane ProteinsLipasemedicine.diseasedigestive system diseasesSurgerybusiness
researchProduct

A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells

2016

Phosphatase and tensin homolog (PTEN) gene is considered a tumor suppressor gene. However, PTEN mutations rarely occur in hepatocellular carcinoma (HCC), whereas heterozygosity of PTEN, resulting in reduced PTEN expression, has been observed in 32–44% of HCC patients. In the present study, we investigated the effects of the small molecule PTEN inhibitor VO-OHpic in HCC cells. VO-OHpic inhibited cell viability, cell proliferation and colony formation, and induced senescence-associated β-galactosidase activity in Hep3B (low PTEN expression) and to a lesser extent in PLC/PRF/5 (high PTEN expression) cells, but not in PTEN-negative SNU475 cells. VO-OHpic synergistically inhibited cell viability…

0301 basic medicineMAPK/ERK pathwayPTENCarcinoma HepatocellularsenescenceTumor suppressor geneCell SurvivalMicePhosphatidylinositol 3-Kinases03 medical and health sciences0302 clinical medicineReportOrganometallic CompoundsAnimalsHumansPTENTensinViability assayHCCProtein kinase BMolecular BiologyPI3K/AKT/mTOR pathwayCell ProliferationbiologyCell growthTOR Serine-Threonine KinasesAKTLiver NeoplasmsPTEN PhosphohydrolaseCell BiologySorafenibXenograft Model Antitumor Assaysdigestive system diseasesVO-OHpicGene Expression Regulation Neoplastic030104 developmental biology030220 oncology & carcinogenesisbiology.proteinCancer researchSignal TransductionDevelopmental Biology
researchProduct

Identification of an LPS-Induced Chemo-Attractive Peptide from Ciona robusta

2020

Background: Previously published work has demonstrated that the LPS injection of Ciona robusta leads to the overexpression of a truncated form of an immune-related mRNA (C8short) by means of Ciona robusta (CR) alternative polyadenylation (APA) (CR-APA). Methods: The 3D structure of the C8short-derived Ciona robusta chemo-attractive peptide (CrCP) was evaluated by homology modeling. The biological activity of the CrCP was studied in vitro using a primary human dermal cell line (HuDe). Real-Time PCR was used to investigate the expression levels of genes involved in cell motility. NF-&kappa

In silicoPharmaceutical ScienceMotilitychemoattractive peptide03 medical and health sciencesAdapter molecule crk0302 clinical medicineWestern blotDrug DiscoverymedicineNF-kBCiona robustaPharmacology Toxicology and Pharmaceutics (miscellaneous)<i>Ciona robusta</i>lcsh:QH301-705.5030304 developmental biology0303 health sciencesmedicine.diagnostic_testChemistryfungiIn vitro3D modellingCell biologyBlotlcsh:Biology (General)Cell cultureinflammation030220 oncology & carcinogenesisSignal transductionCiona robusta; inflammation; chemoattractive peptide; NF-kB; 3D modellingMarine Drugs
researchProduct

Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor ce…

2010

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Celecoxib (Celebrex®) exhibits antitumor effects in human HCC cells, and its mechanism of action is mediated either by its ability to inhibit cyclooxygenase 2 (COX-2) or by a number of various other COX-2 independent effects. Proteasome inhibitors (PIs) can exert cell growth inhibitory and apoptotic effects in different tumor cell types, including HCC cells. The present study examined the interaction between celecoxib and the PI MG132 in two human liver tumor cell lines HepG2 and HA22T/VGH. Our data showed that each inhibitor reduced proliferation and induced apoptosis in a dose-dependen…

MG132TRB3Programmed cell deathLeupeptinsBlotting WesternApoptosisUPRPharmacologyCysteine Proteinase Inhibitorschemistry.chemical_compoundMG132medicineHumansViability assayHCCMolecular BiologyCell ProliferationSettore MED/12 - GastroenterologiaGene knockdownSulfonamidesbiologyCyclooxygenase 2 InhibitorsCell growthReverse Transcriptase Polymerase Chain ReactionDrug SynergismCell BiologyHep G2 CellsCOX-2ER stress responseFlow CytometryapoptosiproteasomechemistryApoptosisCelecoxibSettore BIO/14 - Farmacologiabiology.proteinProteasome inhibitorPyrazolesCyclooxygenaseDevelopmental Biologymedicine.drug
researchProduct

Two single nucleotide polymorphisms in the MICA gene and sMICA plasma levels are associated with hepatocellular carcinoma development in an Italian p…

2017

Background &amp; Aims: We investigated the relationships between MICA polymorphisms, sMICA levels and hepatocellular carcinoma (HCC) risk in HCC patients with chronic hepatitis C virus (HCV) infection. Methods.154 HCV-related HCC cases, 93 HCV-related liver cirrhosis (LC) cases and 244 healthy controls were genotyped using KASPTM SNP method. Levels of plasma soluble MICA (sMICA) were measured in 132 HCC, 90 LC patients and in 78 controls. Results. Genotyping of MICA rs2596542 showed that G/G genotype was significantly more frequent in HCC than in controls and in HCC than in LC patients. As for MICA rs2596538 allele C and C/C genotype were significantly more frequent in HCC than in controls …

Settore MED/09 - Medicina InternaHCC liver cirrhosis HCV single nucleotide polymorphisms
researchProduct

Identification of Type I and IX Collagens in the Ascidian Ciona intestinalis

2001

Immunohistochemical methods showed that a type I collagen is a component of the tunic of Ciona intestinalis, involved in the encapsulation process. Since the fibril-forming collagen types are characterized by triple helical domain with a highly preserved Gly-Xaa-Yaa repeated sequence, a probe coding the fibril-forming type I collagen of the echinoderm Paracentrotus lividus was used to identify ascidian cDNA clones. Northern blot hybridization established that P. lividus probe cross-hybridizes with a 6 Kb C. intestinalis mRNA isolated from the pharynx. Using the echinodermal type I collagen cDNA as a probe several positive clones were identified. Analysis of sequence and the deduced amino ac…

chemistry.chemical_classificationbiologychemistryComplementary DNACiona intestinalisNorthern blotbiology.organism_classificationRepeated sequenceMolecular biologyHomology (biology)Paracentrotus lividusType I collagenAmino acid
researchProduct

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance

2012

// James A. McCubrey 1 , Linda S. Steelman 1 , William H. Chappell 1 , Stephen L. Abrams 1 , Richard A. Franklin 1 , Giuseppe Montalto 2 , Melchiorre Cervello 3 , Massimo Libra 4 , Saverio Candido 4 , Grazia Malaponte 4 , Maria C. Mazzarino 4 , Paolo Fagone 4 , Ferdinando Nicoletti 4 , Jorg Basecke 5 , Sanja Mijatovic 6 , Danijela Maksimovic-Ivanic 6 , Michele Milella 7 , Agostino Tafuri 8 , Francesca Chiarini 9 , Camilla Evangelisti 9 , Lucio Cocco 10 , Alberto M. Martelli 9,10 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA 2 Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy 3 Consi…

MAPK/ERK pathwaymedicine.medical_treatmentPI3KTargeted therapyTargeted therapyPhosphatidylinositol 3-Kinases0302 clinical medicineNeoplasmsTreatment resistanceExtracellular Signal-Regulated MAP KinasesPhosphoinositide-3 Kinase InhibitorsGenetics0303 health sciencesbiologyCancer stem cellsTOR Serine-Threonine KinasesMAP Kinase Kinase KinasesDiscovery and development of mTOR inhibitorshumanities3. Good healthOncology030220 oncology & carcinogenesismTORSignal TransductionProto-Oncogene Proteins B-rafReviewsAntineoplastic Agents03 medical and health sciencesCell Line TumormedicineHumansPTENProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biologybusiness.industryAkt; Cancer stem cells; mTOR; PI3K; Raf; Targeted therapy; Therapy resistanceAktPTEN PhosphohydrolaseTherapy resistanceRafProtein phosphatase 2Targeted Therapy Therapy Resistance Cancer Stem Cells Raf Akt PI3K mTORDrug Resistance NeoplasmMutationras ProteinsCancer researchbiology.proteinbusinessProto-Oncogene Proteins c-akt
researchProduct

The NF-kB inhibitors curcumin and DHMEQ exert antitumor synergy with cisplatin in hepatic cancer cells. Analysis of relationship to IL-6 production.

2006

researchProduct

Emerging MEK inhibitors

2010

IMPORTANCE OF THE FIELD: The Ras/Raf/MEK/ERK pathway is often activated by genetic alterations in upstream signaling molecules. Integral components of this pathway such as Ras and B-Raf are also activated by mutation. The Ras/Raf/MEK/ERK pathway has profound effects on proliferative, apoptotic and differentiation pathways. This pathway can often be effectively silenced by MEK inhibitors. AREAS COVERED BY THIS REVIEW: This review will discuss targeting of MEK which could lead to novel methods to control abnormal proliferation which arises in cancer and other proliferative diseases. This review will cover the scientific literature from 1980 to present and is a follow on from a review which fo…

MAPK/ERK pathwayCell signalingAntineoplastic Agentsmedicine.disease_causemekerkEnzyme activatorNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansPharmacology (medical)Protein phosphorylationProtein Kinase InhibitorsMEK inhibitorsCell ProliferationCancerPharmacologyapoptosis; cancer; erk; kinases; mek; mek inhibitors; proliferative disorders; protein phosphorylation; signal transductionproliferative disordersMutationKinasebusiness.industryapoptosisApoptosiCancerDrugs InvestigationalMAP Kinase Kinase Kinasesmedicine.diseaseprotein phosphorylationCell biologyEnzyme ActivationTreatment OutcomekinasesChemotherapy AdjuvantRadiotherapy AdjuvantSignal transductionbusinesssignal transductionExpert Opinion on Emerging Drugs
researchProduct

Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells.

2019

Abstract Pancreatic cancer is devastating cancer worldwide with few if any truly effective therapies. Pancreatic cancer has an increasing incidence and may become the second leading cause of death from cancer. Novel, more effective therapeutic approaches are needed as pancreatic cancer patients usually survive for less than a year after being diagnosed. Control of blood sugar levels by the prescription drug metformin in diseases such as diabetes mellitus has been examined in association with pancreatic cancer. While the clinical trials remain inconclusive, there is hope that certain diets and medications may affect positively the outcomes of patients with pancreatic and other cancers. Other…

0301 basic medicineCancer ResearchSettore MED/09 - Medicina Internaendocrine system diseasesBerberineSignal transduction inhibitorsBlood sugarPharmacologyAMP-Activated Protein KinasesBerberine; PDAC; Signal transduction inhibitors; TP5303 medical and health scienceschemistry.chemical_compound0302 clinical medicineBerberineMETFORMINAPancreatic cancerDiabetes mellitusGeneticsmedicineHumansTP53Signal transduction inhibitorMolecular BiologyCell Proliferationbusiness.industryPDACCancerAMPKmedicine.diseaseMetforminMetforminNeoplasm ProteinsPancreatic Neoplasms030104 developmental biologychemistry030220 oncology & carcinogenesisCancer cellMolecular Medicinebusinessmedicine.drugAdvances in biological regulation
researchProduct

Cloning and expression of a type IX-like collagen in tissues of the ascidian Ciona intestinalis

2002

Collagens are highly preserved proteins in invertebrates and vertebrates. To identify the collagens in urochordates, the total RNA extracted from the pharynx of the ascidian Ciona intestinalis was hybridized with a heterologous probe specific for the echinoderm Paracentrotus lividus fibrillar type I-like larval collagen. Using this probe, two main bands (i.e. 6 and 2.8 kb mRNA) were observed on Northern blot hybridization. The cDNA library prepared from poly(A)+RNA extracted from pharyngeal tissue was screened and a cDNA that specifies a type IX-like collagen was identified. This molecule presents a conceptual open reading frame for a protein containing 734 amino acids. In particular, we sh…

Transcription GeneticAscidianMolecular Sequence DataBiophysicsIn situ hybridizationcDNA libraryBiochemistryCollagen Type IXMiceStructural BiologyComplementary DNAGeneticsAnimalsHumansCiona intestinalisTissue DistributionNorthern blotAmino Acid SequenceRNA MessengerCloning MolecularType IX-like collagenPeptide sequencePhylogenyGene LibraryMessenger RNAbiologyBase SequenceSequence Homology Amino AcidcDNA libraryRNAbiology.organism_classificationMolecular biologyCiona intestinalismRNA localizationSequence Alignment
researchProduct

Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: Possible role in…

2005

im: To investigate the association of cyclooxygenase-2 (COX-2) expression with angiogenesis and the number and type of inflammatory cells (macrophages/Kupffer cells; mast cells) within primary hepatocellular carcinoma (HCC) tissues and adjacent non-tumorous (NT) tissues. Methods: Immunohistochemistry for COX-2, CD34, CD68 and mast cell tryptase (MCT) was performed on 14 well-characterized series of liver-cirrhosis-associated HCC patients. COX-2 expression and the number of inflammatory cells in tumor lesions and surrounding liver tissues of each specimen were compared. Moreover, COX-2, CD34 staining and the number of inflammatory cells in areas with different histological degrees within eac…

MaleLiver CancerPathologymedicine.medical_specialtyCarcinoma HepatocellularEndotheliumMacrophageAngiogenesisKupffer CellsNeovascularizationCarcinomamedicineHumansMast CellsHCCAgedInflammationbiologyNeovascularization Pathologicbusiness.industryMacrophagesLiver NeoplasmsGastroenterologyMembrane ProteinsGeneral MedicineCOX-2Middle Agedmedicine.diseasedigestive system diseasesAngiogenesimedicine.anatomical_structureMembrane proteinCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesHepatocellular carcinomabiology.proteinTumor promotionFemaleCyclooxygenaseEndothelium Vascularmedicine.symptombusiness
researchProduct

Cancer therapy and treatments during COVID-19 era

2020

The COVID-19 pandemic has put a serious strain on health treatments as well at the economies of many nations. Unfortunately, there is not currently available vaccine for SARS-Cov-2/COVID-19. Various types of patients have delayed treatment or even routine check-ups and we are adapting to a virtual world. In many cases, surgeries are delayed unless they are essential. This is also true with regards to cancer treatments and screening. Interestingly, some existing drugs and nutraceuticals have been screened for their effects on COVID-19. Certain FDA approved drugs, vitamin, natural products and trace minerals may be repurposed to treat or improve the prevention of COVID-19 infections and disea…

0301 basic medicineCancer ResearchDiseaseComorbidityAntineoplastic Agent0302 clinical medicineRepurposing approved drugNeoplasmsPandemicMedicineViralCancerNatural productsVitaminsSpike GlycoproteinHost-Pathogen InteractionDrug repositioning030220 oncology & carcinogenesisHost-Pathogen InteractionsSpike Glycoprotein CoronavirusMolecular MedicineNutraceuticalAngiotensin-Converting Enzyme 2NutraceuticalsCoronavirus InfectionsHumanHydroxychloroquineSignal Transductionmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralAntineoplastic AgentsPeptidyl-Dipeptidase AAntiviral AgentsNatural productVitaminArticle03 medical and health sciencesBetacoronavirusGeneticsHumansIntensive care medicineMolecular BiologyPandemicsTrace ElementAntiviral AgentBetacoronaviruCoronavirus Infectionbusiness.industrySARS-CoV-2CanceRepurposing approved drugsDrug RepositioningrNatural productsCancerCOVID-19Pneumoniamedicine.diseaseComorbidityReview articleTrace ElementsCoronavirus030104 developmental biologyGene Expression RegulationSettore BIO/14 - FarmacologiaNeoplasmbusinessSpike Glycoprotein Coronaviru
researchProduct

IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma.

2011

Recently, a link between high levels of circulating IL-6 and hepatocellular carcinoma (HCC) has been proposed. In addition, single nucleotide polymorphisms (SNPs) in the promoter region of the IL-6 gene have been reported to be related to several inflammatory-related conditions, including cancer. The purpose of this article is: (1) to evaluate the frequencies of SNPs in the IL-6 promoter region at position -174 and IL-6 serum levels in a group of patients with HCC and underlying liver cirrhosis (LC), and compare them with a group of LC patients without HCC; (2) to determine whether a possible correlation exists between the allelic variations, IL-6 serum levels, and the risk of developing HC…

Liver CirrhosisMaleCirrhosisCarcinoma HepatocellularGenotypeSNPSingle-nucleotide polymorphismEnzyme-Linked Immunosorbent AssayBioinformaticsBiochemistryPolymerase Chain ReactionPolymorphism Single NucleotideGene FrequencyGeneticsmedicineHumansAlleleHCCInterleukin 6Molecular BiologyGeneIL-6biologyInterleukin-6Liver NeoplasmsPromotermedicine.diseaseHepatocellular carcinomabiology.proteinCancer researchIL-6 -174G/C polymorphism liver cirrhosis hepatocellular carcinomaMolecular MedicineFemaleRestriction fragment length polymorphismPolymorphism Restriction Fragment LengthBiotechnology
researchProduct

Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells

2014

Hepatocellular carcinoma (HCC) is characterized by limited response to current drug therapies. Here, we report that SC66, a novel AKT inhibitor, reduced cell viability in a dose- and time-dependent manner, inhibited colony formation and induced apoptosis in HCC cells. SC66 treatment led to a reduction in total and phospho-AKT levels. This was associated with alterations in cytoskeleton organization, a reduction in expression levels of E-cadherin, β-catenin and phospho-FAK, together with up-regulation of Snail protein levels. All these alterations were coupled with anoikis cell death induction. In addition, SC66 induced the production of reactive oxygen species (ROS) and DNA damage. Pre-trea…

MaleProgrammed cell deathCarcinoma HepatocellularCytoskeleton organizationPyridinesMice NudeApoptosisBiologyMice03 medical and health sciences0302 clinical medicineanoikisCell Line TumorAnimalsHumansAnoikisViability assayHCCProtein Kinase InhibitorsProtein kinase BPI3K/AKT/mTOR pathwayCell Proliferation030304 developmental biologySC660303 health sciencesCyclohexanonesCell growthAKTLiver NeoplasmsXenograft Model Antitumor AssaysMolecular biology3. Good healthOncologyApoptosis030220 oncology & carcinogenesismTORCancer researchHCC AKT mTOR SC66 anoikisProto-Oncogene Proteins c-aktResearch Paper
researchProduct

Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells

2015

Pancreatic cancer is currently the fourth most common cancer, is increasing in incidence and soon will be the second leading cause of cancer death in the USA. This is a deadly malignancy with an incidence that approximates the mortality with 44,000 new cases and 36,000 deaths each year. Surgery, although only modestly successful, is the only curative option. However, due the locally aggressive nature and early metastasis, surgery can be performed on less than 20% of patients. Cytotoxic chemotherapy is palliative, has significant toxicity and improves survival very little. Thus new treatment paradigms are needed desperately. Due to the extremely high frequency of KRAS gene mutations (>90%) d…

MAPK/ERK pathwayCancer ResearchmiRsEGFRmedicine.disease_causeMetastasisProto-Oncogene Proteins p21(ras)Glycogen Synthase Kinase 3GeneticCancer stem cellKRaPancreatic cancerKRasGeneticsmedicineAnimalsHumansPTENEpidermal growth factor receptorMolecular BiologyPI3K/AKT/mTOR pathwayGSK-3biologyCancer stem cellsCancer stem cellmiRCancer stem cells; Drug resistance; EGFR; GSK-3; KRas; Metformin; miRsmedicine.diseaseMetforminErbB ReceptorsPancreatic NeoplasmsDrug resistanceNeoplastic Stem Cellsbiology.proteinCancer researchMolecular MedicineKRASSignal TransductionAdvances in Biological Regulation
researchProduct

Poly (ADP-ribose) polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells

2014

Poly (ADP-ribose) polymerase (PARP) enzymes play a key role in the cellular machinery responsible for DNA repair. Dehydroxymethylepoxyquinomicin (DHMEQ), a new inhibitor of NF-κB, induces oxidative stress and DNA damage. The effects of DHMEQ in combination with Olaparib (PARP inhibitor) were studied on hepatocellular carcinoma (HCC) cells. The DHMEQ-Olaparib combination synergistically inhibited cell viability, cell proliferation and colony formation of Hep3B, but had additive effects on Huh7 cells. The synergistic effects of the combination correlated with increased apoptosis, caspase 3/7 activity and PARP cleavage. There was an induction of an endoplasmic reticulum (ER) stress response wi…

DHMEQDNA repairDNA damagePoly ADP ribose polymeraseBiologyHepatocellular carcinoma cellNF-κBOlaparib03 medical and health scienceschemistry.chemical_compoundOlaparib0302 clinical medicineViability assayMolecular Biology030304 developmental biology0303 health sciencesCell growthAKTCell BiologyMolecular biologydigestive system diseases3. Good healthchemistryApoptosis030220 oncology & carcinogenesisPARP inhibitorRad51Cancer researchBiochimica et Biophysica Acta (BBA) - Molecular Cell Research
researchProduct

SYNTHESIS AND CHARACTERIZATION OF POLYAMINOACIDIC POLYCATIONS FOR GENE DELIVERY

2005

The properties as non viral gene vector of a protein-like polymer, the alpha,beta-poly(N-2-hydroxyethyl)-d,l-aspartamide (PHEA) were exploited after its derivatization with 3-(carboxypropyl)trimethyl-ammonium chloride (CPTA) as molecule bearing a cationic group, in order to obtain stable polycations able to condense DNA. PHEA was firstly functionalized with aminic pendant groups by reaction with ethylenediamine (EDA) obtaining the alpha,beta-poly(N-2-hydroxyethyl)(2-aminoethylcarbamate)-d,l-aspartamide (PHEA-EDA) copolymer. We demonstrated that polymer functionalization degree is easily modulable by varying reaction conditions, so allowing to produce two PHEA-EDA derivatives at different mo…

Materials scienceBiophysicsBioengineeringEthylenediamineGene deliveryPolycationBiomaterialschemistry.chemical_compoundGene DeliveryPolymer chemistryPolyaminesTumor Cells CulturedCopolymerHumansAspartameCytotoxicityEndodeoxyribonucleasesGene Transfer TechniquesCationic polymerizationDNACondensation reactionPolyelectrolytesPolyelectrolytechemistryMechanics of MaterialsCeramics and CompositesAmine gas treating
researchProduct

Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma

2017

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world, and represents the second most frequently cancer and third most common cause of death from cancer worldwide. At advanced stage, HCC is a highly aggressive tumor with a poor prognosis and with very limited response to common therapies. Therefore, there is still the need for new effective and well-tolerated therapeutic strategies. Molecular-targeted therapies hold promise for HCC treatment. One promising molecular target is the multifunctional serine/threonine kinase glycogen synthase kinase 3 (GSK-3). The roles of GSK-3β in HCC remain controversial, several studies suggested a possible role of GSK-3β as a tumor …

0301 basic medicinePathologymedicine.medical_specialtyCancer ResearchCarcinoma HepatocellularEpithelial-Mesenchymal TransitionTumor suppressor geneAntineoplastic Agentsmacromolecular substancesBiologyMetastasisGlycogen Synthase Kinase 303 medical and health sciencesWnt0302 clinical medicineGeneticTransforming Growth Factor betaGSK-3GeneticsmedicineHumansHedgehog ProteinsMolecular Targeted TherapyInsulin-Like Growth Factor IHCCIGFβ-cateninGlycogen synthaseHedgehogMolecular Biologybeta CateninGSK-3Glycogen Synthase Kinase 3 betaReceptors NotchLiver NeoplasmsWnt signaling pathwayCancermedicine.diseaseSurvival Analysisdigestive system diseasesGene Expression Regulation Neoplastic030104 developmental biology030220 oncology & carcinogenesisHepatocellular carcinomabiology.proteinCancer researchMolecular MedicineHedgehogSignal Transduction
researchProduct

Association Between Single Nucleotide Polymorphisms in the Cyclooxygenase-2, Tumor Necrosis Factor-α, and Vascular Endothelial Growth Factor-A Genes,…

2011

Cyclooxygenase-2 (COX-2), vascular endothelial growth factor-A (VEGF-A), and tumor necrosis factor-α (TNF-α) are mediators of inflammation and angiogenesis; all of them are produced in liver cirrhosis (LC) and in hepatocellular carcinoma (HCC). It was proposed that there is an association between single nucleotide polymorphisms (SNPs) and HCC. These allelic variants influence the transcriptional activity of these genes, and therefore the proteins levels. The VEGF-A pathway is a potential therapeutic target in HCC, and several antiangiogenic agents have entered clinical trials in HCC. We evaluated the frequency of SNPs of COX-2, TNF-α, and VEGF-A genes in patients with HCC versus LC patients…

MaleVascular Endothelial Growth Factor AHeterozygoteCarcinoma HepatocellularCirrhosisAngiogenesisSingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideBiochemistryCOX-2 TNFa VEGF Hepatocellular Carcinoma SNPsGeneticsmedicineHumansneoplasmsMolecular BiologyTumor Necrosis Factor-alphaHomozygoteLiver Neoplasmsnucleotide polymorphisms cyclooxygenase-2 tumor necrosis factor-α vascular endothelial growth factor-A geneshepatocellular carcinoma.Heterozygote advantagemedicine.diseasedigestive system diseasesVascular endothelial growth factor ACyclooxygenase 2Hepatocellular carcinomaImmunologyCancer researchMolecular MedicineFemaleTumor necrosis factor alphaRestriction fragment length polymorphismBiotechnologyOMICS: A Journal of Integrative Biology
researchProduct

Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of β-caten…

2004

Proteasome inhibitors, like MG132, can exert cell growth inhibitory and apoptotic effects in different tumor types. The apoptotic mechanism of these compounds involves the activation of the effector caspases. beta-catenin, also an oncogene, represents one of the substrates of these proteases, but the consequences of its cleavage are poorly understood. We investigated its function during apoptosis induced by MG132 in three hepatocellular carcinoma (HCC) cell lines, endowed (HepG2 and HuH-6) or not (HA22T/VGH) with activating mutations of beta-catenin. Induction of apoptosis was associated with cell growth inhibition, accumulation of the cells at the G(2)/M phases of the cell cycle, as well a…

hepatocellular carcinoma ß-catenin apoptosis proteasome MG132 survivinSettore MED/09 - Medicina InternabiologyCell growthGeneral MedicineCell cycleCell biologychemistry.chemical_compoundProteasomechemistryApoptosisMG132SurvivinGeneticsProteasome inhibitormedicineCancer researchbiology.proteinCaspasemedicine.drug
researchProduct

Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relat…

2005

The hepatic cancer HA22T/VGH cell line, which constitutively expresses activated nuclear factor-kappaB (NF-kB), was chosen as a model to examine the antitumor activity of curcumin, also in relationship to its possible influences on the activation of the transcription factor and on the expression of the inhibitory of apoptosis proteins (IAPs) and of other NF-kB target genes. Curcumin exerted cell growth inhibitory and apoptotic effects, related, at least part, to free radical generation and mainly dependent on caspase-9 and -3 activation. The combination of curcumin with cisplatin resulted in a synergistic antitumor activity and that with doxorubicin in additivity or sub-additivity. Curcumin…

Cancer ResearchCurcuminHepatocellular carcinomaAntineoplastic AgentsBiologyInhibitor of Apoptosis Proteinschemistry.chemical_compoundGene expressionmedicineTumor Cells CulturedHumansDoxorubicinDrug InteractionsNF-kBCell ProliferationCisplatinAntibiotics AntineoplasticCell growthLiver NeoplasmsNF-kappa BProteinsInhibitory of apoptosis proteinMolecular biologyXIAPGene Expression Regulation NeoplasticOncologychemistryApoptosisDoxorubicinCancer cellCurcuminCancer researchCisplatinmedicine.drugCancer letters
researchProduct

Properties of sea urchin coelomocyte agglutinins

1996

We examined some biological activities of a 200-kDa glycoprotein, referred to as Paracentrotus lividus vitellogenin, contained both in the coelomic fluid and in a subpopulation of coelomocytes called «colourless spherula cells». Cell-free coelomic fluid, coelomocyte lysate and supernatant obtained after coelomocyte washings were assayed for hemagglutinating activity. All samples agglutinated rabbit erythrocytes in a calcium-dependent way. The comparison between the electrophoretic patterns of erythrocyte lysates, before and after incubation with the coelomic fluid, revealed that a 200-kDa band was obtained from membranes of agglutinated erythrocytes. In addition, polyclonal antibodies again…

chemistry.chemical_classificationcoelomocytebiologymedicine.diagnostic_testbiology.organism_classificationMolecular biologyParacentrotus lividussea urchinagglutininimmune systemVitellogeninAgglutininchemistryWestern blotPolyclonal antibodiesbiology.animalbiology.proteinmedicineadhesion moleculesAnimal Science and ZoologyGlycoproteinSea urchinCoelomocytegrainineItalian Journal of Zoology
researchProduct

RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma

2019

Introduction: Hepatocellular carcinoma (HCC) is a significant problem globally because of viral infections and the increasing incidence of obesity and fatty liver disease. However, it is difficult to treat because its inherent genetic heterogeneity results in activation of numerous signaling pathways. Kinases have been targeted for decades with varying results, but the development of therapeutic resistance is a major challenge. Areas covered: The key roles of the RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1, TP53 microRNAs (miRs) as therapeutic targets are discussed and we suggests novel approaches for targeting miRs or their downstream targets to combat HCC. We performed literature searches using…

0301 basic medicineMAPK/ERK pathwayCarcinoma HepatocellularHepatocellular carcinmamedicine.medical_treatmentClinical BiochemistryAntineoplastic AgentsmTORC1signal transduction inhibitorsTargeted therapy03 medical and health sciences0302 clinical medicineDrug DiscoverymicroRNAmedicinePTENAnimalsHumanscancerMolecular Targeted TherapyTP53HCCRAS/RAF/MEK/ERKProtein kinase BPI3K/AKT/mTOR pathwaymiRNAPharmacologybiologybusiness.industryKinaseLiver NeoplasmsMirhepatocellular carcinomatargeted therapyGene Expression Regulation NeoplasticMicroRNAssignal transduction inhibitor030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisbiology.proteinCancer researchMolecular MedicinePI3K/PTEN/AKTbusinessSignal Transduction
researchProduct

215 CYCLOOXYGENASE-2, TUMOR NECROSIS FACTOR-a, VASCULAR ENDOTHELIAL GROWTH FACTOR-A AND IL-6 GENES SNPS AND IL-6 SERUM LEVELS IN LIVER CIRRHOSIS AND …

2011

Oncologymedicine.medical_specialtyCirrhosisHepatologybiologybusiness.industrySingle-nucleotide polymorphismmedicine.diseaseVascular endothelial growth factor AHepatocellular carcinomaInternal medicinebiology.proteinCancer researchmedicineTumor necrosis factor alphaCyclooxygenaseInterleukin 6businessGeneJournal of Hepatology
researchProduct

Association between MICA Gene Variants and the Risk of Hepatitis C Virus-Induced Hepatocellular Cancer in a Sicilian Population Sample

2018

There are currently no biomarkers that predict hepatocellular carcinoma (HCC) risk in patients with hepatitis C virus (HCV)-related cirrhosis. We investigated the relationships among major histocompatibility complex (MHC) class I chain-related gene A (MICA) polymorphisms, plasma levels of soluble MICA (sMICA), and HCC risk in patients with HCV-related HCC. One hundred fifty-four HCV-related HCC patients, 93 HCV-related liver cirrhosis (LC) cases, and 244 healthy controls, all sampled from the native Sicilian population, were genotyped using the KASP™ single-nucleotide polymorphism genotyping method. The MICA rs2596542 polymorphism showed that the G/G genotype was significantly more frequent…

Liver CirrhosisMale0301 basic medicineGenetic LinkageHepacivirusHepacivirusmedicine.disease_causeGastroenterologyBiochemistryLinkage DisequilibriumMiceLiver disease0302 clinical medicineGenotypeOdds RatioAged 80 and overeducation.field_of_studybiologyHepatitis Chepatocellular carcinomaMiddle AgedHepatitis CItalyPopulation Surveillance030220 oncology & carcinogenesisHepatocellular carcinomagenetic association studyHCVMolecular MedicineFemaleDisease SusceptibilityCell-Free Nucleic AcidsBiotechnologymedicine.medical_specialtyCarcinoma HepatocellularGenotypeHepatitis C virusPopulation03 medical and health sciencesInternal medicinemedicineGeneticsAnimalsHumanseducationMolecular BiologyAllelesAgedbusiness.industryliver cirrhosiDecision TreesHistocompatibility Antigens Class IGenetic VariationOdds ratiomedicine.diseasebiology.organism_classificationdigestive system diseases030104 developmental biologyMICAbusinessBiomarkers
researchProduct

“Antitumor effects of curcumin in human hepatic cancer cells: Analysis of their relationship to inhibition of NF-kB and pro-survival gene expression”.

2005

researchProduct

Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity—Diverse effects on cell growth, metabolism and cancer

2016

Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase that participates in an array of critical cellular processes. GSK-3 was first characterized as an enzyme that phosphorylated and inactivated glycogen synthase. However, subsequent studies have revealed that this moon-lighting protein is involved in numerous signaling pathways that regulate not only metabolism but also have roles in: apoptosis, cell cycle progression, cell renewal, differentiation, embryogenesis, migration, regulation of gene transcription, stem cell biology and survival. In this review, we will discuss the roles that GSK-3 plays in various diseases as well as how this pivotal kinase interacts with multiple sign…

0301 basic medicineMAPK/ERK pathwaySettore MED/06 - Oncologia MedicaCellular differentiationPI3KTargeted therapyGlycogen Synthase Kinase 3Phosphatidylinositol 3-Kinases0302 clinical medicineGSK-3Neoplasmsbeta CateninGSK-3biologyReceptors NotchKinaseWnt signaling pathwayWnt/beta-cateninCell DifferentiationCell biologyGene Expression Regulation Neoplastic030220 oncology & carcinogenesismTORAkt; GSK-3; Hedgehog; Notch; PI3K; Targeted therapy; Therapy resistance; Wnt/beta-catenin; mTORSignal TransductionBeta-cateninNotchAkt GSK-3 Hedgehog mTOR Notch PI3K Targeted therapy Therapy resistance Wnt/beta-cateninCell Survivalmacromolecular substancesNO03 medical and health sciencesAkt; GSK-3 Hedgehog Notch PI3K Targeted therapy Therapy resistance Wnt/beta-catenin mTORAnimalsHumansHedgehog ProteinsProtein kinase BMolecular BiologyPI3K/AKT/mTOR pathwayCell ProliferationAktTherapy resistanceAkt; GSK-3; Hedgehog; mTOR; Notch; PI3K; Targeted therapy; Therapy resistance; Wnt/beta-catenin; Molecular Biology; Cell BiologyCell BiologyWnt ProteinsMicroRNAs030104 developmental biologyMutationCancer researchbiology.proteinTumor Suppressor Protein p53Hedgehog
researchProduct

Outcome predictors in SARS-CoV-2 disease (COVID-19): The prominent role of IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population

2022

Microbiology (medical)Polymorphism GeneticSettore MED/09 - Medicina InternaInfectious DiseasesCOVID-19.Interleukin-6SARS-CoV-2HumanJournal of Infection
researchProduct

New agents and approaches for targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR cell survival pathways.

2012

The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Targeting these pathways is often complex and can result in pathway activation depending on the presence of upstream mutations (e.g., Raf inhibitors induce Raf activation in cells with wild type (WT) RAF in the presence of mutant, activated RAS) and rapamycin can induce Akt activation. Targeting with inhibitors directed at two constituents of the same pathway or two different signaling pathways may be a more effective approach. This review will first evaluate potential uses of Raf, MEK, PI3K, Akt and mTOR inhibitors that have…

MAPK/ERK pathway0303 health sciencesCell signalingbiologyChemistryAKTApoptosisGrowth factorRafOncogens: Signaling pathway3. Good healthMalignant transformation03 medical and health sciences0302 clinical medicineApoptosis030220 oncology & carcinogenesisCancer researchbiology.proteinEpidermal growth factor receptorSignal transductionpi3kProtein kinase BRaPI3K/AKT/mTOR pathway030304 developmental biology
researchProduct

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

2013

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells. The present study examined the interaction between celecoxib and sorafenib in two human liver tumor cell lines HepG2 and Huh7. Our data showed that each inhibitor alone reduced cell growth and the combination of celecoxib with sorafenib synergistically inhibited cell growth an…

medicine.medical_treatmentCancer TreatmentGene ExpressionApoptosisPharmacologyBiochemistryTargeted therapy0302 clinical medicineMolecular Cell Biology0303 health sciencesSulfonamidesMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionQLiver NeoplasmsRDrug SynergismGenomicsSorafenib3. Good healthGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMedicineLiver cancermedicine.drugResearch ArticleBiotechnologySignal TransductionSorafenibNiacinamideProgrammed cell deathCarcinoma HepatocellularScienceBlotting WesternBiologyMolecular Genetics03 medical and health sciencesCell Line TumorGastrointestinal TumorsmedicineIn Situ Nick-End LabelingHumansneoplasmsBiology030304 developmental biologyCell ProliferationDNA PrimersHuman liver cancer Apoptosis Sorafenib Celecoxib anti-proliferative effectsCell growthGene Expression ProfilingPhenylurea CompoundsComputational BiologyCancers and NeoplasmsHepatocellular CarcinomaChemotherapy and Drug Treatmentmedicine.diseaseMicroarray Analysisdigestive system diseasesGene expression profilingApoptosisCell cultureCelecoxibPyrazolesGenome Expression AnalysisPLoS ONE
researchProduct

Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells.

2018

Berberine (BBR) is a common nutraceutical consumed by millions worldwide. BBR has many different effects on human health, e.g., diabetes, diarrhea, inflammation and now more recently it has been proposed to have potent anti-cancer effects. BBR has been shown to suppress the growth of cancer cells more than normal cells. BBR has been proposed to exert its growth-inhibitory effects by many different biochemical mechanisms including: suppression of cell cycle progression, induction of reactive oxygen species, induction of apoptosis and autophagy and interactions with DNA potentially leading to DNA damage, and altered gene expression. Pancreatic cancer is a leading cancer worldwide associated w…

Male0301 basic medicineCancer ResearchSettore MED/09 - Medicina InternaBerberineDNA damagePopulationSignal transduction inhibitorsApoptosisInflammation03 medical and health sciences0302 clinical medicineCell Line TumorPancreatic cancerGeneticsmedicineHumanseducationChemotherapeutic drugMolecular BiologySignal transduction inhibitorAgededucation.field_of_studybusiness.industryCell CycleAutophagyCancerPDACDNA Neoplasmmedicine.diseaseGene Expression Regulation NeoplasticPancreatic Neoplasms030104 developmental biologyApoptosis030220 oncology & carcinogenesisCancer cellCancer researchMolecular MedicineChemotherapeutic drugsmedicine.symptombusinessDNA DamageSignal Transduction
researchProduct

Serum concentration of E-selectin in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma

2000

Objectives: High levels of soluble E-selectin have been reported in acute and chronic inflammatory disorders. Moreover, in some types of tumor elevated values have been found while in other types reduced levels have been reported. Our aims were to determine whether soluble E-selectin levels might be useful in monitoring the progression of chronic liver disease, including hepatocellular carcinoma. Methods: Circulating soluble E-selectin was measured by an enzyme-linked immunosorbent assay in the sera of 18 patients with chronic hepatitis, 44 with liver cirrhosis, and 38 with hepatocellular-carcinoma-associated liver cirrhosis. Immunohistochemical localization of E-selectin was also performed…

AdultLiver CirrhosisMaleCancer Researchmedicine.medical_specialtyPathologyCarcinoma HepatocellularCirrhosismedicine.medical_treatmentChronic liver diseaseInternal medicineE-selectinmedicineHumansAgedHepatitisHematologybiologybusiness.industryLiver NeoplasmsGeneral MedicineHepatitis C ChronicMiddle Agedmedicine.diseaseCytokineOncologyCase-Control StudiesHepatocellular carcinomabiology.proteinImmunohistochemistryFemaleE-SelectinbusinessBiomarkersJournal of Cancer Research and Clinical Oncology
researchProduct

Circulating, intercellular adhesion molecule-1 in patients with hepatocellular carcinoma

1997

Intercellular adhesion molecule-1 (ICAM-1) is thought to play an important role in cellular immunological reactions. Expression can be induced by inflammatory cytokines in a wide variety of cells, including hepatocytes.To compare the behaviour of ICAM-1 in liver diseases.We assayed serum ICAM-1 (sICAM-1) in patients with hepatocellular carcinoma-associated liver cirrhosis, and compared them with a group of cirrhotic patients and controls. sICAM-1 values were also correlated with some biochemical parameters of liver function. Moreover, immunohistochemical localization of ICAM-1 was performed on liver tissue sections of patients with hepatocellular carcinoma, liver cirrhosis and a sample of n…

AdultLiver CirrhosisMalePathologymedicine.medical_specialtyCarcinoma HepatocellularCirrhosisIntercellular Adhesion Molecule-1Chronic liver diseaseLiver diseasemedicineCarcinomaHumansEndotheliumAgedHepatologymedicine.diagnostic_testbusiness.industryLiver NeoplasmsGastroenterologyAlanine TransaminaseBilirubingamma-GlutamyltransferaseMiddle AgedAlkaline PhosphataseIntercellular Adhesion Molecule-1medicine.diseaseImmunohistochemistryHepatocellular carcinomaFemalealpha-FetoproteinsLiver functionLiver function testsbusiness
researchProduct

Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation

2017

The beneficial health properties of the Mediterranean diet are well recognized. The principle source of fat in Mediterranean diet is extra-virgin olive oil (EVOO). Oleocanthal (OC) is a naturally occurring minor phenolic compound isolated from EVOO, which has shown a potent anti-inflammatory activity, by means of its ability to inhibit the cyclooxygenase (COX) enzymes COX-1 and COX-2. A large body of evidence indicates that phenols exhibit anticancer activities. The aim of the present study was to evaluate the potential anticancer effects of OC in hepatocellular carcinoma (HCC) and colorectal carcinoma (CRC) models. A panel of human HCC (HepG2, Huh7, Hep3B and PLC/PRF/5) and CRC (HT29, SW48…

0301 basic medicineCancer ResearchCarcinoma HepatocellularHepatocellular carcinomaOleocanthalExtra-virgin olive oilCellApoptosisCyclopentane Monoterpenes03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePhenolsOleocanthalmedicineHumansCyclooxygenase InhibitorsViability assayOlive OilCaspaseCell ProliferationAldehydesbiologyCell growthLiver NeoplasmsApoptosiHep G2 CellsCell cycledigestive system diseasesColorectal carcinoma030104 developmental biologymedicine.anatomical_structureOncologychemistryApoptosisCell culture030220 oncology & carcinogenesisImmunologybiology.proteinCancer researchReactive oxygen specieColorectal NeoplasmsReactive Oxygen SpeciesDNA DamageInternational Journal of Oncology
researchProduct

GDF11 induces mild hepatic fibrosis independent of metabolic health

2020

BACKGROUND & AIMS: Growth Differentiation Factor 11 (GDF11) is an anti-aging factor, yet its role in liver diseases is not established. We evaluated the role of GDF11 in healthy conditions and in the transition from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH). RESULTS: GDF11 mRNA levels positively correlated with NAFLD activity score and with CPT1, SREBP, PPAR? and Col1A1 mRNA levels, and associated to portal fibrosis, in morbidly obese patients with NAFLD/NASH. GDF11-treated mice showed mildly exacerbated hepatic collagen deposition, accompanied by weight loss and without changes in liver steatosis or inflammation. GDF11 triggered ALK5-dependent SMAD2/…

Liver CirrhosisMaleAgingSettore MED/09 - Medicina Interna*liverLiver Cirrhosis ExperimentalFetgeWeight lossFibrosisfibrosis; growth differentiation factor 11; liver; NAFLD; NASHNon-alcoholic Fatty Liver DiseaseGrowth differentiation factor 11Fatty liverNASH*fibrosisMiddle AgedObesity MorbidGrowth Differentiation FactorsLiverBone Morphogenetic ProteinsDisease ProgressionFemalemedicine.symptomResearch PaperSignal TransductionAdultmedicine.medical_specialtygrowth differentiation factor 11Inflammationliverdigestive systemCell LineEnvellimentInternal medicineNAFLDmedicineHepatic Stellate CellsAnimalsHumansddc:612*growth differentiation factor 11business.industry*NAFLDfibrosisnutritional and metabolic diseasesCell Biologyliver NAFLD NASH fibrosis growth differentiation factor 11*NASHmedicine.diseaseFibrosisdigestive system diseasesMice Inbred C57BLEndocrinologyPortal fibrosisCase-Control StudiesGDF11Hepatic stellate cellSteatohepatitisHepatic fibrosisbusiness
researchProduct

Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine

2012

Neutrophil gelatinase-associated lipocalin (NGAL, a.k.a Lnc2) is a member of the lipocalin family and has diverse roles. NGAL can stabilize matrix metalloproteinase-9 from autodegradation. NGAL is considered as a siderocalin that is important in the transport of iron. NGAL expression has also been associated with certain neoplasias and is implicated in the metastasis of breast cancer. In a previous study, we examined whether ectopic NGAL expression would alter the sensitivity of breast epithelial, breast and colorectal cancer cells to the effects of the chemotherapeutic drug doxorubicin. While abundant NGAL expression was detected in all the cells infected with a retrovirus encoding NGAL, t…

BenzylaminesBerberinemedicine.medical_treatmentDrug ResistanceGene ExpressionBCL-2; Berberine; Breast cancer; Calmodulin kinase; Colorectal cancer; EGFR; Inhibitor sensitivity; Lcn2; Lipocalins; NGAL; Rapamycin; Siderocalins; Targeted therapyPiperazinesMetastasisTargeted therapyNitrophenolsTargeted therapyBreast cancerAntibioticsNGALSulfonamidesAntibiotics AntineoplasticTumorSiderocalinsTyrphostinsAntineoplasticLipocalinsBiphenyl compoundErbB ReceptorsProto-Oncogene Proteins c-bcl-2MCF-7 CellsFemalelipocalinHT29 Cellsmedicine.drugbcl-2; breast cancer; lipocalins; targeted therapy; berberine; lcn2; colorectal cancer; rapamycin; inhibitor sensitivity; siderocalins; egfr; ngal; calmodulin kinaseCalmodulin kinasesiderocalinEGFRBCL-2Breast NeoplasmsSiderocalinBiologyNGAL Lcn2 lipocalins siderocalins targeted therapy inhibitor sensitivity EGFR rapamycin berberine BCL-2 calmodulin kinase breast cancer colorectal cancerCell LineHT29 CellsLcn2Lipocalin-2ReportCell Line TumorProto-Oncogene ProteinsmedicineHumansDoxorubicinRapamycinMolecular BiologyProtein Kinase InhibitorsSirolimusBiphenyl CompoundsCell Biologymedicine.diseaseColorectal cancerCell cultureDoxorubicinDrug Resistance NeoplasmCancer cellCalcium-Calmodulin-Dependent Protein KinasesCancer researchQuinazolinesNeoplasmInhibitor sensitivityDevelopmental BiologyAcute-Phase Proteins
researchProduct

NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response

2021

AbstractBackground and AimsNon-alcoholic fatty liver disease and related hepatic syndromes affect up to one third of the adult population. The molecular mechanisms underlying NAFL etiology remain elusive. Nuclear Protein 1 (NUPR1) expression increases upon cell injury in all organs and recently we report its active participation in the activation of the Unfolded Protein Response (UPR). The UPR typically maintains protein homeostasis, but downstream mediators of the pathway regulate metabolic functions, including lipid metabolism. NUPR1 and UPR increase have been reported in obesity and liver pathologies and the goal of this study was to investigate the roles of NUPR1 in this context.Methods…

0301 basic medicinemedicine.medical_specialtySettore MED/09 - Medicina InternaPPAR-a signalling UPRPeroxisome proliferator-activated receptorContext (language use)UPRDiet High-FatBiochemistry03 medical and health sciencesLiver diseaseMice0302 clinical medicineInternal medicineCell Line TumorGeneticsmedicineBasic Helix-Loop-Helix Transcription FactorsAnimalsHomeostasisHumansMolecular Biologychemistry.chemical_classificationbusiness.industryEndoplasmic reticulumFatty liverNASHLipid metabolismlipotoxicitymedicine.diseaseEndoplasmic Reticulum StressLipid MetabolismNeoplasm Proteins030104 developmental biologyEndocrinologychemistryLipotoxicityLiverNAFLKnockout mouseUnfolded protein responseUnfolded Protein ResponsePPAR-a signallingSteatosisSteatohepatitisbusiness030217 neurology & neurosurgeryNUPR1Biotechnology
researchProduct

COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells.

2011

Celecoxib (Celebrex((R)), Pfizer) is a selective cyclooxygenase-2 (COX-2) inhibitor with chemopreventive and antitumor effects. However, it is now well known that celecoxib has several COX-2-independent activities. To better understand COX-2-independent molecular mechanisms underlying the antitumor activity of celecoxib, we investigated the expression profile of the celecoxib-treated COX-2-positive (Huh7) and COX-2-negative (HepG2) liver cancer cell lines, using microarray analysis. Celecoxib treatment resulted in significantly altered expression levels of 240 and 403 transcripts in Huh7 and HepG2 cells, respectively. Confirmation of the microarray results was performed for selected genes b…

Programmed cell deathCarcinoma HepatocellularMicroarrayTranscription GeneticHepatocellular carcinomaCell SurvivalAntineoplastic AgentsPharmacologyBiologyBiochemistryCell Line TumorGeneticsmedicineHumansMode of actionneoplasmsMolecular BiologySulfonamidesCyclooxygenase 2 InhibitorsCell growthMicroarray analysis techniquesGene Expression ProfilingLiver NeoplasmsCOX-2Gene expression profilingGene Expression Regulation NeoplasticCell cultureCelecoxibCyclooxygenase 2CelecoxibMolecular MedicinePyrazolesBiotechnologymedicine.drugSignal TransductionOmics : a journal of integrative biology
researchProduct

Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery.

2007

In this paper, the suitability of novel cationic solid-lipid nanoparticles (SLN) as a nonviral transfection agent for gene delivery was investigated. SLN were produced by using the microemulsion method and Compritol ATO 888 as matrix lipid, dimethyldioctadecylammonium bromide as charge carrier and Pluronic F68 as surfactant. Obtained nanoparticles were approximately 120 nm in size and positively charged, with a zeta potential value equal to +45 mV in twice-distilled water. Cationic SLN were able to form stable complexes with DNA and to protect DNA against DNase I digestion. The SLN-DNA complexes were characterized by mean diameter and zeta potential measurements. In vitro studies on human l…

Cell SurvivalPharmaceutical ScienceGene deliveryBiologyTransfectionGlyceridesPulmonary surfactantCationsCell Line TumorSolid lipid nanoparticleZeta potentialHumansParticle Sizeeducationeducation.field_of_studyDrug CarriersGenetic transferCationic polymerizationGene Transfer TechniquesTransfectionDNAlipid nanoparticles gene deliverybeta-GalactosidaseBiochemistryBiophysicsNanoparticlesDimethyldioctadecylammonium bromideJournal of drug targeting
researchProduct

Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis

2014

The EGFR/PI3K/PTEN/Akt/mTORC pathway plays prominent roles in malignant transformation, prevention of apoptosis, drug resistance, cancer initiating cells (CICs) and metastasis. The expression of this pathway is frequently altered in breast and other cancers due to mutations at or aberrant expression of: HER2, EGFR1, PIK3CA, and PTEN as well as other oncogenes and tumor suppressor genes. miRs and epigenetic mechanisms of gene regulation are also important events which regulate this pathway. In some breast cancer cases, mutations at certain components of this pathway (e.g., PIK3CA) are associated with a better prognosis than breast cancers lacking these mutations. The expression of this pathw…

MaleOncologyCancer Researchmedicine.medical_treatmentTargeted therapyMetastasisTargeted therapyBreast cancerNeoplasmsNeoplasm MetastasisCancer stem cellsMedicine (all)Neoplasm ProteinsNeoplasm MetastasiGene Expression Regulation NeoplasticCell Transformation NeoplasticMolecular MedicineFemaleHormonal therapyHumanSignal Transductionmedicine.medical_specialtyEGFRBiologyNeoplasm ProteinBreast cancerGeneticCancer stem cellInternal medicineHER2GeneticsmedicineAnimalsHumansPTENMolecular BiologyProtein kinase BPI3K/AKT/mTOR pathwayCell ProliferationAnimalCancer stem cellTherapy resistanceCancermedicine.diseaseERDrug Resistance NeoplasmBreast cancer; Cancer stem cells; EGFR; ER; HER2; Hormonal therapy; Targeted therapy; Therapy resistancebiology.proteinCancer researchNeoplasm
researchProduct

Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma

2018

Hepatocellular carcinoma (HCC) is a highly malignant tumor that responds very poorly to existing therapies, most probably due to its extraordinary inter- and intra-tumor molecular heterogeneity. The modest therapeutic response to molecular targeted agents underlines the need for new therapeutic approaches for HCC. In our study, we took advantage of well-characterized human HCC cell lines, differing in transcriptomic subtypes, DNA mutation and amplification alterations, reflecting the heterogeneity of primary HCCs, to provide a preclinical evaluation of the specific heat shock protein 90 (HSP90) inhibitor AUY922 (luminespib). Indeed, HSP90 is highly expressed in different tumor types, but it…

p53MaleCancer ResearchCellTranscriptome0302 clinical medicineHCCbeta CateninAged 80 and overLuminespibAUY922Liver NeoplasmsHep G2 CellsSorafenibMiddle AgedUp-RegulationGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyCaspases030220 oncology & carcinogenesisHepatocellular carcinomaFemaleNUPR1medicine.drugAdultSorafenibCarcinoma Hepatocellularβ-CateninMice NudeAntineoplastic AgentsSmall Molecule Libraries03 medical and health sciencesDownregulation and upregulationIn vivoCell Line TumormedicineHSP90AnimalsHumansHSP90 Heat-Shock ProteinsAgedCell growthbusiness.industryMcl-1IsoxazolesResorcinolsHCCSmedicine.diseasedigestive system diseasesMutationCancer researchTranscriptomebusinessInternational Journal of Cancer
researchProduct

Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.

2017

Abstract In this paper, we describe the preparation of polymeric nanoparticles (NPs) loaded with sorafenib for the treatment of hepatocellular carcinoma (HCC). A synthetic brush copolymer, named PHEA-BIB-ButMA (PBB), was synthesized by Atom Trasnfer Radical Polymerization (ATRP) starting from the α-poly( N -2-hydroxyethyl)- d , l -aspartamide (PHEA) and poly butyl methacrylate (ButMA). Empty and sorafenib loaded PBB NPs were, then, produced by using a dialysis method and showed spherical morphology, colloidal size, negative ζ potential and the ability to allow a sustained sorafenib release in physiological environment. Sorafenib loaded PBB NPs were tested in vitro on HCC cells in order to e…

3003MaleHepatocellular carcinomamedicine.medical_treatmentPharmaceutical Science02 engineering and technologyATRPPharmacology01 natural sciencesDrug Delivery SystemsCopolymerChemistryATRP; Hepatocellular carcinoma; Sorafenib; Tumor targeting; α-Poly(N-2-hydroxyethyl)-DL-aspartamide; 3003Liver NeoplasmsSorafenib021001 nanoscience & nanotechnologyDrug delivery0210 nano-technologymedicine.drugSorafenibNiacinamideCarcinoma HepatocellularCell SurvivalRadical polymerizationIntraperitoneal injectionL-aspartamideMice NudeAntineoplastic AgentsEnhanced permeability and retention effect010402 general chemistryPolymethacrylic AcidsIn vivoCell Line TumormedicineAnimalsHumansneoplasmsProtein Kinase InhibitorsPhenylurea Compoundstechnology industry and agriculturedigestive system diseasesIn vitro0104 chemical sciencesDrug LiberationTumor targetingDelayed-Action PreparationsBiophysicsα-Poly(N-2-hydroxyethyl)-DNanoparticlesα-Poly(N-2-hydroxyethyl)-DL-aspartamidePeptidesJournal of controlled release : official journal of the Controlled Release Society
researchProduct

The clinical impact of an extra virgin olive oil enriched mediterranean diet on metabolic syndrome: Lights and shadows of a nutraceutical approach

2022

For years it has been established that the only truly effective treatment of metabolic syndrome (MS) is lifestyle modification to prevent its cardiovascular (e.g., coronary artery disease and atherosclerosis), metabolic (e.g., diabetes mellitus), and hepatic (e.g., steatosis and non-alcoholic steatohepatitis) complications. The focal points of this approach are to increase physical activity and intake of a diet characterized by high quantities of fruits, vegetables, grains, fish, and low-fat dairy products, the so called mediterranean diet (MD); however, the added value of MD is the presence of extra virgin olive oil (EVOO), a healthy food with a high content of monounsaturated fatty acids,…

functional foodSettore MED/09 - Medicina InternaNutrition and Dieteticsnutraceuticals.cardiovascular diseaseinsulin resistanceEndocrinology Diabetes and Metabolismextra virgin olive oil (EVOO)metabolic syndromeFood ScienceFrontiers in Nutrition
researchProduct

Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53

2020

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic malignancy. Approximately 85% of pancreatic cancers are classified as PDACs. The survival of PDAC patients is very poor and only 5–10% of patients survive 5 years after diagnosis. Mutations at the KRAS and TP53 gene are frequently observed in PDAC patients. The PANC-28 cell line lacks wild-type (WT) TP53. In the following study, we have investigated the effects of restoration of WT TP53 activity on the sensitivity of PANC-28 pancreatic cancer cells to various drugs which are used to treat PDAC patients as well as other cancer patients. In addition, we have examined the effects of signal transduction inhibitors which tar…

Male0301 basic medicineDrugCancer ResearchmiRsendocrine system diseasesmedia_common.quotation_subjectSignal transduction inhibitorsTargeted therapeuticAntineoplastic AgentsMalignancymedicine.disease_causeProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineChloroquinePancreatic cancerGeneticsmedicineHumansTP53Molecular BiologyneoplasmsSignal transduction inhibitorTargeted therapeuticsCell Proliferationmedia_commontarget therapeuticsCell growthbusiness.industryCancermedicine.diseasedigestive system diseasesMetforminPancreatic Neoplasms030104 developmental biology030220 oncology & carcinogenesisDietary SupplementsMutationCancer researchmiRs.Molecular MedicineFemaleKRASTumor Suppressor Protein p53businessSignal Transductionmedicine.drugDrug sensitivity
researchProduct

From Targets to Targeted Therapies in Hepatocellular Carcinoma

2014

MAPK/ERK pathwaybusiness.industrymedicine.medical_treatmentRPTORmedicine.diseaseBiochemistryTargeted therapyHepatocellular carcinomaGeneticsCancer researchMolecular MedicineMedicinebusinessBiotechnologyForum on Immunopathological Diseases and Therapeutics
researchProduct

The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods

2020

Background. Bariatric surgery patients have a higher prevalence of nonalcoholic fatty liver (NAFL) than the general population; however, its assessment and the accurate staging of fibrosis are often complicated because noninvasive tests are not very accurate in patients with morbid obesity, and liver biopsy cannot be performed as a routine exam. The aim of this study was to evaluate (A) the histological prevalence of NAFL, nonalcoholic steatohepatitis (NASH), and fibrosis in patients undergoing bariatric surgery; (B) the reliability of ultrasound (US) in diagnosing NAFL; and (C) the reliability of various fibrosis scoring systems for defining fibrosis. Methods. US and intraoperative liver b…

AdultMalemedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaArticle SubjectPopulationBariatric SurgeryPrevalence NAFLD Fibrosis Bariatric Surgery Non invasive diagnosis UltrasoundGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseDiabetes mellitusNonalcoholic fatty liver diseasemedicinePrevalenceHumansObesityeducationNonalcoholic steatohepatitis (NASH)Retrospective StudiesUltrasonographyeducation.field_of_studyGeneral Immunology and Microbiologymedicine.diagnostic_testbusiness.industryFatty liverRRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseFibrosisSurgeryObesity Morbidultrasound (US)ROC Curve030220 oncology & carcinogenesisLiver biopsyMedicine030211 gastroenterology & hepatologyFemalebusinessResearch ArticleNonalcoholic fatty liver disease (NAFLD)BioMed Research International
researchProduct

Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pa…

2019

Improving the effects of chemotherapy and reducing the side effects are important goals in cancer research. Various approaches have been examined to enhance the effectiveness of chemotherapy. For example, signal transduction inhibitors or hormonal based approaches have been included with chemo- or radio-therapy. MIA-PaCa-2 and BxPC-3 pancreatic ductal adenocarcinoma (PDAC) cells both express the estrogen receptor (ER). The effects of β-estradiol on the growth of PDAC cells has not been examined yet the ER is expressed in PDAC cells. We have examined the effects of combining β-estradiol with chemotherapeutic drugs, signal transcription inhibitors, natural products and nutraceuticals on PDAC.…

0301 basic medicineCancer Researchendocrine system diseasesβ estradiolmedicine.medical_treatmentβ-EstradiolEstrogen receptorAntineoplastic AgentsNatural product03 medical and health sciencesFood-Drug Interactions0302 clinical medicineNutraceuticalPancreatic cancerCell Line TumorGeneticsmedicineHumansMolecular BiologyChemotherapeutic drugCell ProliferationChemotherapyNatural products?-EstradiolEstradiolbusiness.industryQUIMIOTERÁPICOSChemotherapeutic drugs; Natural products; Nutraceuticals; Pancreatic cancer; β-EstradiolPancreatic cancerMiddle Agedmedicine.diseasedigestive system diseasesPancreatic Neoplasms030104 developmental biology030220 oncology & carcinogenesisDietary SupplementsCancer researchSettore BIO/14 - FarmacologiaMolecular MedicineChemotherapeutic drugsFemaleChemotherapeutic drugsNutraceuticalsNutraceuticalSignal transductionbusinessHormoneCarcinoma Pancreatic DuctalSignal TransductionAdvances in biological regulation
researchProduct

Hepatocellular Carcinoma: A Difficult Cancer to Treat

2021

Hepatocellular carcinoma (HCC) is a very peculiar cancer because it presents several molecular alterations linked to the activation of survival and antiapoptotic signal pathways that are protein in form and not easily targetable by even the newest targeted therapies. In addition, it is almost always a consequence of liver cirrhosis, a serious disease condition in which several drugs are often not tolerated. This is why the study of HCC was such a challenge for Professor Natale D'Alessandro, to whom this work is dedicated, during the latter years of his career. The aim of this review is to summarize studies on different molecules involved in the development, progression, and chemoresistance …

Liver CirrhosisCancer ResearchCarcinoma HepatocellularCirrhosisDruggabilityDrug resistanceNuclear factor κbDiseaseYY1medicineHumansInterleukin 6IL-6drug resistancebiologybusiness.industryLiver NeoplasmsCancerhepatocellular carcinomamedicine.diseasedigestive system diseasescyclooxygenasesHepatocellular carcinomaNF-?Bbiology.proteinCancer researchEpatocarcinoma ciclossigenasi NF-kB IL-6 farmacoresistenza YY1businessSignal TransductionCritical Reviews™ in Oncogenesis
researchProduct

Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prost…

2020

Background TP53 plays critical roles in sensitivity to chemotherapy, and aging. Collagen is very important in aging. The molecular structure and biochemical properties of collagen changes during aging. The discoidin domain receptor (DDR1) is regulated in part by collagen. Elucidating the links between TP53 and DDR1 in chemosensitivity and aging could improve therapies against cancer and aging. Results Restoration of WT-TP53 activity resulted in increased sensitivity to chemotherapeutic drugs and elevated expression of key components of the Raf/MEK/ERK, PI3K/Akt and DDR1 pathways. DDR1 could modulate the levels of Raf/MEK/ERK and PI3K/Akt pathways as well as sensitize the cells to chemothera…

MAPK/ERK pathwayMalecollagenAgingRAF/MEK/ERKMAP Kinase Signaling SystemAntineoplastic Agentsdiscoidin domain receptor (DDR1)DDRCollagen receptorPhosphatidylinositol 3-KinasesDiscoidin Domain Receptor 1Cell Line TumorHumansRapamycinTP53ReceptorProtein kinase BPI3K/AKT/mTOR pathwayDDR1ChemistryWild typeProstateProstatic NeoplasmschemoresistanceCell Biologyprostate cancerDrug Resistance NeoplasmMutationCancer researchraf KinasesTumor Suppressor Protein p53Discoidin domainResearch Paper
researchProduct

Truncated Form of beta-Catenin and Reduced Expression of Wild-Type Catenins Feature HepG2 Human Liver Cancer Cells

2000

Pathologymedicine.medical_specialtyCarcinoma HepatocellularBeta-cateninbiologyChemistryGeneral NeuroscienceLiver NeoplasmsWild typemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyCell biologyCytoskeletal ProteinsHuman liver cancerHistory and Philosophy of ScienceCateninTrans-Activatorsbiology.proteinmedicineCarcinomaHumansTrans-Activatorsbeta CateninAnnals of the New York Academy of Sciences
researchProduct

Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition …

2007

The molecular mechanisms behind the anti-neoplastic effects of non-steroidal anti-inflammatory drugs (NSAIDs) are not completely understood and cannot be explained by the inhibition of the cyclooxygenase (COX) enzymes COX-1 and COX-2 alone. We previously reported that both the selective COX-1 inhibitor SC-560 and the selective COX-2 inhibitor CAY10404 exhibit anti-tumor effects in human hepatoma cells. NSAID inhibitors have many COX-independent actions and, among others, the mitogen-activated protein kinase (MAPK) pathways are targets for NSAIDs. Here, we examined the role of MEK/ERK1/2 signaling in the anti-neoplastic effects of both selective COX-1 and COX-2 inhibitors in two human hepato…

MAPK/ERK pathwayCancer ResearchCarcinoma HepatocellularTime FactorsBlotting WesternApoptosisPharmacologyCOX-1 COX-2 NSAIDs MEK1/2 ERK1/2NitrilesButadienesTumor Cells CulturedHumansCyclooxygenase InhibitorsSulfonesEnzyme InhibitorsPhosphorylationProtein kinase ACell ProliferationPharmacologychemistry.chemical_classificationMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase KinasesMitogen-Activated Protein Kinase 3biologyDose-Response Relationship DrugLiver NeoplasmsCytochromes cLong-term potentiationDrug SynergismIsoxazolesFlow CytometryEnzymeOncologychemistryCyclooxygenase 2CaspasesCancer cellbiology.proteinCyclooxygenase 1Molecular MedicineMEK-ERK PathwayPyrazolesDrug Therapy CombinationCyclooxygenaseHepatoma cellCancer biologytherapy
researchProduct

Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of…

2021

Abstract Approaches to improve pancreatic cancer therapy are essential as this disease has a very bleak outcome. Approximately 80% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC). A key regulatory gene frequently mutated (∼75%) in PDAC is the TP53 tumor suppressor gene which controls the transcription of multiple genes involved in cell cycle progression, apoptosis, cancer progression and other growth regulatory processes. The mouse double minute 2 homolog (MDM2) gene product is a nuclear-localized E3 ubiquitin ligase and negatively regulates the TP53 protein which results in its proteasomal degradation. Various MDM2 inhibitors have been isolated and examined in clinical t…

Nutlin-3aCancer ResearchBerberineendocrine system diseasesTumor suppressor geneNAX compoundsApoptosisPiperazinesTargeted therapyGene productCell Line TumorPancreatic cancerGeneticsmedicineHumansTP53neoplasmsMolecular BiologyRegulator geneNAX compundsbiologyChemistryImidazolesPDACCancerProto-Oncogene Proteins c-mdm2PDCAmedicine.diseaseUbiquitin ligasePancreatic NeoplasmsCell culturebiology.proteinCancer researchNAX compoundMolecular MedicineMdm2Tumor Suppressor Protein p53Signal TransductionAdvances in Biological Regulation
researchProduct

Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling

2020

The epidermal growth factor receptor (EGFR) interacts with various downstream molecules including phospholipase C (PLC)/protein kinase C (PKC), Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/GSK-3, Jak/STAT and others. Often these pathways are deregulated in human malignancies such as breast cancer. Various therapeutic approaches to inhibit the activity of EGFR family members including small molecule inhibitors and monoclonal antibodies (MoAb) have been developed. A common problem with cancer treatments is the development of drug-resistance. We examined the effects of a conditionally-activated EGFR (v-Erb-B:ER) on the resistance of breast cancer cells to commonly used chemotherapeutic drugs such as doxorub…

0301 basic medicineMAPK/ERK pathwayEGFRvIIICancer ResearchEGFREstrogen receptorAntineoplastic AgentsBreast Neoplasms03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerCell Line TumorGeneticsHumansMedicinePTENEpidermal growth factor receptorskin and connective tissue diseasesMolecular BiologyProtein kinase BPI3K/AKT/mTOR pathwaybiologybusiness.industryCancermedicine.diseaseErbB Receptors030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisDrug resistancebiology.proteinCancer researchMolecular MedicineFemalebusinessSignal TransductionV-Erb-B
researchProduct

The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma

2021

The multikinase inhibitor sorafenib was the first drug approved by the FDA for treating patients with advanced hepatocellular carcinoma (HCC). However, sorafenib resistance remains a major challenge for improving the effectiveness of HCC treatment. Previously, we identified several genes modulated after sorafenib treatment of human HCC cells, including the stress-inducible nuclear protein 1 (NUPR1) gene. Multiple studies have shown that NUPR1 regulates autophagy, apoptosis, and chemoresistance. Here, we demonstrate that treatment of HCC cells with sorafenib resulted in the activation of autophagic flux. NUPR1 knock-down (KD) in HCC cells was associated with increased p62 expression, suggest…

SorafenibCancer ResearchCarcinoma HepatocellularSettore MED/09 - Medicina InternaHepatocellular carcinomap73Mice NudeApoptosisSettore BIO/11 - Biologia MolecolareMiceNSC5594In vivoPumaBasic Helix-Loop-Helix Transcription FactorsmedicineAutophagyNSC5994AnimalsHumansGene silencingneoplasmsbiologyActivator (genetics)business.industryLiver NeoplasmsAutophagyApoptosiTumor Protein p73Hep G2 CellsSorafenibbiology.organism_classificationmedicine.diseasedigestive system diseasesNeoplasm ProteinsOncologyDrug Resistance NeoplasmApoptosisHepatocellular carcinomaCancer researchFemalebusinessNUPR1medicine.drug
researchProduct

Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs

2017

Natural products or nutraceuticals have been shown to elicit anti-aging, anti-cancer and other health-enhancing effects. A key target of the effects of natural products may be the regulation of microRNA (miR) expression which results in cell death or prevents aging, diabetes, cardiovascular and other diseases. This review will focus on a few natural products, especially on resveratrol (RES), curcumin (CUR) and berberine (BBR). RES is obtained from the skins of grapes and other fruits and berries. RES may extend human lifespan by activating the sirtuins and SIRT1 molecules. CUR is isolated from the root of turmeric (Curcuma longa). CUR is currently used in the tutreatment of many disorders, …

0301 basic medicineAgingCurcuminMiRReviewResveratrolPharmacologyCSCNatural productCell LineNOMiRs03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBerberineNutraceuticalCancer stem cellCell Line TumorNeoplasmsmicroRNAHumansMedicineSIRTGene methylationCurcumaNatural productsTumorCSCs Curcumin Gene methylation MiRs Natural products Resveratrol SIRTbiologybusiness.industryCell BiologyCoptis chinensisbiology.organism_classificationCSCs; Curcumin; Gene methylation; MiRs; Natural products; Resveratrol; SIRT; Aging; Cell Line Tumor; Humans; Neoplasms; Neoplastic Stem Cells; Dietary Supplements030104 developmental biologychemistryResveratrol030220 oncology & carcinogenesisDietary SupplementsNeoplastic Stem CellsCurcuminCSCsbusinessAging
researchProduct

Cyclooxygenase-2 expression in chronic liver disease and hepatocellular carcinoma: an immunohistochemical study

2009

UNLABELLED Hepatocarcinogenesis is a multistep process characterized by hepatocyte inflammation, regeneration, and proliferation. These changes are believed to depend on the aberrant expression of various tumor suppressor genes, oncogenes and growth factors. Several studies have shown the involvement of cyclooxygenase-2 (COX-2), the inducible isoform of the enzymes that catalyze prostaglandin synthesis in various aspects of carcinogenesis. COX-2 has been described as being overexpressed in hepatocellular carcinoma (HCC) patients. Using immunohistochemistry, we studied COX-2 expression in different chronic liver diseases (CLD) including nonalcoholic steatohepatitis (NASH), chronic hepatitis …

AdultMalePathologymedicine.medical_specialtyCarcinoma HepatocellularCirrhosisPopulationBiologymedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyLiver diseaseHistory and Philosophy of SciencemedicineHumanscarcinogenesieducationAgededucation.field_of_studyLiver DiseasesGeneral NeuroscienceLiver NeoplasmsCyclooxygenase carcinogenesis liver diseaseMiddle Agedmedicine.diseaseImmunohistochemistrydigestive system diseasesCyclooxygenasemedicine.anatomical_structureCyclooxygenase 2HepatocyteHepatocellular carcinomaChronic Diseasebiology.proteinImmunohistochemistryFemaleCyclooxygenaseCarcinogenesisliver disease
researchProduct

Multifaceted roles of GSK-3 and Wnt/beta-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention

2013

Glycogen synthase kinase-3 (GSK-3) is well documented to participate in a complex array of critical cellular processes. It was initially identified in rat skeletal muscle as a serine/threonine kinase that phosphorylated and inactivated glycogen synthase. This versatile protein is involved in numerous signaling pathways that influence metabolism, embryogenesis, differentiation, migration, cell cycle progression and survival. Recently, GSK-3 has been implicated in leukemia stem cell pathophysiology and may be an appropriate target for its eradication. In this review, we will discuss the roles that GSK-3 plays in hematopoiesis and leukemogenesis as how this pivotal kinase can interact with mul…

MAPK/ERK pathwayCancer ResearchBeta-catenintherapy resistanceCarcinogenesisWnt ProteinReviewmacromolecular substancesAkt; GSK-3; leukemia stem cells; targeted therapy; therapy resistance; Wnt/b-cateninWNTGlycogen Synthase Kinase 3GSK-3PTENAnimalsHumansHematopoiesiProtein kinase BCarcinogenesiPI3K/AKT/mTOR pathwaybeta CateninWnt/β-cateninGSK-3LeukemiabiologyAnimalKinaseAktleukemia stem cellWnt signaling pathwayHematologyleukemia stem cellstargeted therapy3. Good healthHematopoiesisWnt ProteinsAnesthesiology and Pain MedicineOncologyCancer researchbiology.proteinWnt/b-cateninHuman
researchProduct

Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy.

2013

Glycogen synthase kinase-3 (GSK-3) is a critical enzyme which participates in a complex array of important cellular processes and is often involved in various human diseases. It was first characterized in rat skeletal muscle as a serine/threonine (S/T) kinase that phosphorylated and inactivated glycogen synthase (GS). GS is the last enzyme in glycogen biosynthesis . Thus the initially identified role of GSK-3 was in metabolism. However, as we will soon see, GSK-3 has many diverse functions.

Cancer ResearchENZYMECarcinogenesisCancer therapymacromolecular substancesBiologymedicine.disease_causeGSK3law.inventionGlycogen Synthase Kinase 3GeneticlawGSK-3NeoplasmsGeneticsmedicineAnimalsHumansGenes Tumor SuppressorGenes tumor suppressorMolecular BiologyGeneCarcinogenesiAnimalNeoplasms therapyMolecular medicineMetabolismCancer researchNeoplasmMolecular MedicineSuppressorCarcinogenesisGlycogenHumanAdvances in biological regulation
researchProduct

Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis.

2016

TP53 is a critical tumor suppressor gene that regulates cell cycle progression, apoptosis, cellular senescence and many other properties critical for control of normal cellular growth and death. Due to the pleiotropic effects that TP53 has on gene expression and cellular physiology, mutations at this tumor suppressor gene result in diverse physiological effects. T53 mutations are frequently detected in numerous cancers. The expression of TP53 can be induced by various agents used to treat cancer patients such as chemotherapeutic drugs and ionizing radiation. Radiation will induce Ataxia telangiectasia mutated (ATM) and other kinases that results in the phosphorylation and activation of TP53…

0301 basic medicineCancer Researchendocrine system diseasesMetastasimedicine.disease_causeMetastasisAntineoplastic AgentInvasionNeoplasmsTP53Neoplasm Metastasisbcl-2-Associated X ProteinAza CompoundProto-Oncogene ProteinApoptosis Regulatory ProteinbiologyCell CyclemiRMicroRNACell cycleCell biologyNeoplasm MetastasiGene Expression Regulation NeoplasticNutlin-3 chemosensitivityMdm2Molecular MedicineHumanSignal TransductionCyclin-Dependent Kinase Inhibitor p21Tumor suppressor genemiRsAntineoplastic AgentsCellular senescenceTP53; miRs; MDM2; Nutlin-3 chemosensitivity; Cellular senescence ; Invasion; Metastasis03 medical and health sciencesBcl-2-associated X proteinGeneticMDM2Proto-Oncogene ProteinsmicroRNAGeneticsmedicineHumansNeoplasm InvasivenessneoplasmsMolecular BiologyCell ProliferationNeoplasm InvasiveneAza CompoundsOncomirBridged Bicyclo Compounds HeterocyclicMicroRNAs030104 developmental biologyTumor progressionbiology.proteinNeoplasmTumor Suppressor Protein p53CarcinogenesisApoptosis Regulatory Proteins
researchProduct

Metformin influences drug sensitivity in pancreatic cancer cells

2018

Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10% after diagnosis and treatment. Pancreatic cancer has been associated with type II diabetes as the frequency of recently diagnosed diabetics that develop pancreatic cancer within a 10-year period of initial diagnosis of diabetes in increased in comparison to non-diabetic patients. Metformin is a very frequently prescribed drug used to treat type II diabetes. Metformin acts in part by stimulating AMP-kinase (AMPK) and results in the suppression of mTORC1 activity and the induction o…

AMPK0301 basic medicineCancer Researchendocrine system diseases03 medical and health sciencesPancreatic cancerGeneticsMedicineAnimalsHumansDoxorubicinDrug InteractionsRapamycinSignal transduction inhibitormTORC1Molecular BiologyCisplatinSirolimusAnimalbusiness.industryPancreatic NeoplasmCancermedicine.diseaseGemcitabineMetforminMetforminPancreatic Neoplasms030104 developmental biologyDrug InteractionDocetaxelDiabetes Mellitus Type 2SirolimusCancer researchMolecular MedicinebusinessHumanmedicine.drugCarcinoma Pancreatic DuctalSignal Transduction
researchProduct

Critical Roles of EGFR family members in breast cancer and breast cancer stem cells: Targets for therapy

2016

The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980's. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses o…

0301 basic medicineCA15-3OncologyEGFR HER2 mIRs Cancer Stem Cells Drug Resistance Metastasismedicine.medical_specialtyEGFRDrug ResistancemIRCancer Stem CellBreast NeoplasmsNOMetastasisMetastasis03 medical and health sciences0302 clinical medicineBreast cancerCancer stem cellInternal medicineCancer Stem CellsHER2Drug DiscoverymicroRNAmedicineCancer Stem Cells; Drug Resistance; EGFR; HER2; Metastasis; mIRs; Pharmacology; Drug Discovery3003 Pharmaceutical ScienceAnimalsHumansEpidermal growth factor receptorPharmacologyCancer Stem Cells; Drug Resistance; EGFR; HER2; Metastasis; mIRsmIRsbiologybusiness.industryEGFR HER2 mIRs Cancer Stem Cells Drug Resistance Metastasis.Drug Discovery3003 Pharmaceutical ScienceCancermedicine.disease3. Good healthErbB Receptors030104 developmental biology030220 oncology & carcinogenesisbiology.proteinNeoplastic Stem CellsFemaleStem cellbusinessSignal Transduction
researchProduct

Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reac…

2009

Activation of the nuclear transcription factor-kappa B (NF-kappa B) has been implicated in liver tumorigenesis. We evaluated the effects of a novel NF-kappa B inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), in two human liver cancer cell lines HA22T/VGH and HuH-6. DHMEQ treatment dose dependently decreased the DNA-binding capacity of the NF-kappa B p65 subunit, inhibited cell growth and proliferation, and increased apoptosis as shown by caspase activation, release of cytochrome c, poly(ADP-ribose) polymerase cleavage, and down-regulation of survivin. DHMEQ also induced a dose-dependent activation of mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling, …

Programmed cell deathCarcinoma HepatocellularBIOLOGICAL-ACTIVITIESDrug Evaluation PreclinicalDown-RegulationAntineoplastic AgentsApoptosisBiologymedicine.disease_causeACTIVATIONchemistry.chemical_compoundHYDROGEN-PEROXIDEENDOPLASMIC-RETICULUM STRESSCell Line TumorSurvivinNADPH OXIDASEmedicineHumansOXIDATIVE STRESSProtein kinase AEndoplasmic Reticulum Chaperone BiPINDUCED APOPTOSISCell ProliferationPharmacologySettore MED/12 - GastroenterologiaDose-Response Relationship DrugUNFOLDED PROTEIN RESPONSECell growthCyclohexanonesINDUCTIONLiver NeoplasmsDEATHNF-kappa BCytochromes cMolecular biologyCell biologyEnzyme ActivationchemistryApoptosisCaspasesCancer cellBenzamidesSettore BIO/14 - FarmacologiaMolecular MedicineGrowth inhibitionMitogen-Activated Protein KinasesPoly(ADP-ribose) PolymerasesReactive Oxygen SpeciesOxidative stressMolecular pharmacology
researchProduct

A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells

2016

Phosphatase and tensin homolog (PTEN) gene is considered a tumor suppressor gene. However, PTEN mutations rarely occur in hepatocellular carcinoma (HCC), whereas heterozygosity of PTEN, resulting in reduced PTEN expression, has been observed in 32–44% of HCC patients. In the present study, we investigated the effects of the small molecule PTEN inhibitor VO-OHpic in HCC cells. VO-OHpic inhibited cell viability, cell proliferation and colony formation, and induced senescence-associated β-galactosidase activity in Hep3B (low PTEN expression) and to a lesser extent in PLC/PRF/5 (high PTEN expression) cells, but not in PTEN-negative SNU475 cells. VO-OHpic synergistically inhibited cell viability…

digestive system diseases
researchProduct